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Abstract 
The m-AAA protease is a hexameric complex involved in processing of specific 
substrates and turnover of misfolded polypeptides in the mitochondrial inner membrane. 
In humans, the m-AAA protease is composed of AFG3L2 and paraplegin. Mutations in 
AFG3L2 have been implicated in dominant spinocerebellar ataxia (SCA28) and 
recessive spastic ataxia-neuropathy syndrome (SPAX5). Mutations of SPG7, encoding 
paraplegin, are linked to hereditary spastic paraplegia. In the mouse, a third subunit 
AFG3L1 is expressed. Various mouse models recapitulate the phenotype of these 
neurodegenerative disorders, however, the pathogenic mechanism of neurodegeneration 
is not completely understood.  
Here, we studied several mouse models and focused on cell-autonomous role of the m-
AAA protease in neurons and myelinating cells. We show that lack of Afg3l2 triggers 
mitochondrial fragmentation and swelling, tau hyperphosphorylation and pathology in 
Afg3l2 full-body and forebrain neuron-specific knockout mice. Moreover, deletion of 
Afg3l2 in adult myelinating cells causes early-onset mitochondrial abnormalities as in 
the neurons, but the survival of these cells is not affected, which is a contrast to early 
neuronal death. Despite the fact that myelinating cells have been previously shown to 
survive respiratory deficiency by glycolysis, total ablation of the m-AAA protease by 
deleting Afg3l2 in an Afg3l1 null background (DKO), leads to myelinating cell demise 
and subsequently progressive axonal demyelination. Interestingly, DKO mice show 
premature hair greying due to loss of melanoblasts. Together, our data demonstrate cell-
autonomous survival thresholds to m-AAA protease deficiency, and an essential role of 
the m-AAA protease to prevent cell death independent from mitochondrial dynamics 
and the oxidative capacity of the cell. Thus, our findings provide novel insights to the 
pathogenesis of diseases linked to m-AAA protease deficiency, and also establish 
valuable mitochondrial dysfunctional mouse models to study other neurodegenerative 
diseases, such as tauopathies and demyelinating diseases. 
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1.1 Mitochondria 
About 2 billion years ago, ancient bacteria entered primordial eukaryotic cells with a 
symbiotic relationship and evolved into mitochondria, which are semi-autonomous and 
essential organelles in modern eukaryotic cells (Gerdes et al., 2012; Wallace, 2005). In 
humans, although 99% of mitochondrial proteins are encoded by the nuclear genome, 
synthesized in the cytosol and imported into mitochondria, mitochondria maintain a 
genome encoding 13 proteins that are core subunits of respiratory chain complexes I, III, 
IV, and V, but not complex II, which is exclusively composed of proteins encoded by 
nuclear genes (Chan, 2006; Gerdes et al., 2012; Wallace, 2005). The mitochondrial 
DNA (mtDNA) genome also encodes 2 rRNAs and 22 tRNAs that are required for 
translation of mtDNA transcripts (Chan, 2006; Wallace, 2005).  
1.1.1 Mitochondrial function 
The well-known function of mitochodondria is ATP production through the process of 
oxidative phosphorylation (OXPHOS). Moreover, mitochondria participate in diverse 
cellular processes, such as lipid biosynthesis, Ca2+ and iron homeostasis, autophagy and 
apoptosis (Chan, 2006; Rugarli and Langer, 2012). Endoplasmic reticulum (ER) 
regulate mitochondrial morphology and function through the ER-mitochondria contact 
sites (Friedman and Nunnari, 2014). Proper mitochondrial morphology and function are 
extremely required for neurons, which are polarized cells, need high amount of ATP 
and rely on OXPHOS to produce energy (Rugarli and Langer, 2012). However, 
OXPHOS generates reactive oxygen species (ROS) as a by-product, which may in turn 
impair mitochondrial function (Wallace, 2005).  
1.1.2 Mitochondrial quality control 
Cells have a hierarchical system of surveillance mechanisms to prevent mitochondrial 
damage or selectively remove dysfunctional mitochondrial proteins or entire organelles 
under stress (Rugarli and Langer, 2012). At molecular levels, the first line of defense is 
conducted by mitochondrial chaperones and proteases, which promote folding of newly 
imported polypeptides and degrade irreversibly misfolded or damaged proteins (Rugarli 
and Langer, 2012; Tatsuta and Langer, 2008). During protein homeostasis and 
mitochondrial stress, mitochondria communicate with nucleus to activate the expression 
of mitochondrial unfolded protein response (UPRmt) genes, such as chaperones and 
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proteases, to perform intramitochondrial quality control (Quiros et al., 2016; Rugarli 
and Langer, 2012). The UPRmt has been characterized extensively in C. elegans and 
also has been reported in mammalians (Dogan et al., 2014; Quiros et al., 2016). In 
addition, at organellar levels, sustained mitochondrial stress and damage, lead to 
mitochondrial morphological alterations, including hyperfusion and fragmentation, to 
alleviate mild stress or segregate severe damaged mitochondria, which might be 
eliminated by selective autophagy namely mitophagy (Rugarli and Langer, 2012). 
Recently, a novel mitochondrial quality control pathway has been identified, in which 
mitochondria selectively degrade impaired proteins and lipids by generating small 
vesicular carriers that transport mitochondrial proteins and lipids to intracellular 
organelles, such as late endosome and peroxisomes (Sugiura et al., 2014). 
Failure of mitochondrial quality control leads to cell death, and mitochondrial 
dysfunction has been implicated in various neurodegenerative diseases, metabolic 
disorders, ageing, and cancer (Burte et al., 2015; Chan, 2006; Rugarli and Langer, 2012; 
Wallace, 2005). 
1.2 The m-AAA protease 
Mitochondrial proteases, termed mitoproteases, act as key regulators for mitochondrial 
biogenesis, protein quality control, dynamics, mitophagy and apoptosis (Figure 1.1) 
(Martinelli and Rugarli, 2010; Quiros et al., 2015; Rugarli and Langer, 2012; Tatsuta 
and Langer, 2008). Numerous mitoproteases have been identified, and they are 
classified into three categories- intrinsic, transient and pseudo mitoproteases, according 
to their location, function, and structural and proteolytic characteristics (Quiros et al., 
2015). The mitochondrial matrix ATPases associated with diverse cellular activities (m-
AAA) protease is an intrinsic metalloprotease in the inner membrane with the catalytic 
domain facing the matrix (Gerdes et al., 2012; Koppen and Langer, 2007; Martinelli and 
Rugarli, 2010; Quiros et al., 2015). 
1.2.1 The m-AAA protease subunits and function 
In the mouse, the m-AAA protease is a hexameric complex formed by AFG3L1, 
AFG3L2 and paraplegin (Koppen et al., 2007). Whereas in humans, AFG3L1 is 
pseudogene (Kremmidiotis et al., 2001) and the m-AAA protease is composed by 
AFG3L2 and paraplegin. All subunits of the m-AAA protease have similar domains 
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including a mitochondrial targeting sequence, two transmembrane domains, an AAA 
domain and a metal-dependant proteolytic domain (Martinelli and Rugarli, 2010). 
AFG3L1 and AFG3L2 form homo- and hetero-oligomeric complexes, but paraplegin 
can only assemble into hetero-hexamers (Koppen and Langer, 2007; Koppen et al., 
2007) (Figure 1.2). 
In the last decade, the function of m-AAA protease has been broadly explored in yeast, 
cell lines, murine models and human patients. These studies have shown that the m-
AAA protease processes specific substrates and also regulates the turnover of misfolded 
mitochondrial respiratory chain complex subunits. The best-characterized substrate of 
the m-AAA protease is the mitochondrial ribosomal protein MrpL32, which mediates 
ribosome assembly and mitochondrial translation (Almajan et al., 2012; Bonn et al., 
2011; Nolden et al., 2005). The m-AAA protease degrades a truncated form of 
cytochrome c oxidase subunit I (COX1) to maintain mitochondrial protein quality 
control (Hornig-Do et al., 2012). Depletion or mutations of the m-AAA protease harms 
mitochondrial function in multiple aspects, including mitochondrial respiratory chain 
complex deficiency, dynamic disturbance, Ca2+ handling defect, and anterograde 
transport impairment (Atorino et al., 2003; Ehses et al., 2009; Kondadi et al., 2014; 
Maltecca et al., 2015; Maltecca et al., 2012).  
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Figure 1.1 Proteolytic regulation of mitochondrial functions by mitoproteases 
Mitoproteases perform proteolytic reactions to regulate mitochondrial protein import, cardiolipin 
synthesis, protein systhesis, dynamics, mitophagy, apoptosis and mitochondrial DNA (mtNDA) (Quiros 
et al., 2015).  
 
Figure 1.2 Isoenzymes of the m-AAA protease 
In humans, AFG3L2 and paraplegin assemble into homo-oligomeric AFG3L2 and hetero-oligomeric 
AFG3L2/paraplegin complexes. In the mouse, a third subunit AFG3L1 is present. Therefore, five 
isoenzymes of the m-AAA protease have been identified, and the hetero-oligomeric complex composed 
by AFG3L1, AFG3L2 and paraplegin is speculative (indicated by a question mark) (Koppen and Langer, 
2007). 
  
AFG3L2 AFG3L1paraplegin AFG3L2 paraplegin
In humans In the mouse
?
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1.2.2 Human diseases causes by the m-AAA protease mutations 
Mutations of the m-AAA protease subunits have been linked to three rare inherited 
neurodegenerative disorders. In general, these diseases are clinically heterogeneous, and 
the phenotype is variable among affected individuals even within the same family. 
SPG7 gene, maps on chromosome 16q24.3 and encodes for paraplegin, which mutation 
causes autosomal recessive hereditary spastic paraplegia (HSP) characterized by lower 
limb weakness and spasticity due to retrograde degeneration of corticospinal axons 
(Arnoldi et al., 2008; Brugman et al., 2008; Casari et al., 1998; De Michele et al., 1998; 
Elleuch et al., 2006; McDermott et al., 2001; Warnecke et al., 2007; Wilkinson et al., 
2004). So far, more than 30 mutations in SPG7 gene have been found, accounting for 
approximately 5% of autosomal recessive HSP (Salinas et al., 2008; Sánchez-Ferrero et 
al., 2013). Recently, familial analysis from a large cohort of Spanish HSP patients 
suggests a dominant inheritance of SPG7 mutations (Sánchez-Ferrero et al., 2013). The 
onset of HSP patients carrying SPG7 mutations is mostly in the adulthood (mean age, 
30 years), and the range is from 1 year to 77 years (Arnoldi et al., 2008; Brugman et al., 
2008; Casari et al., 1998; De Michele et al., 1998; Elleuch et al., 2006; McDermott et al., 
2001; Sánchez-Ferrero et al., 2013; Warnecke et al., 2007; Wilkinson et al., 2004). 
SPG7 affected individuals may show variable clinical features with both pure and 
complicated HSP (Casari and Marconi, 2006, updated 2010; Harding, 1983). The 
phenotype of pure HSP includes gait disturbance, hyperreflexia, extensor plantar 
responses, and decreased vibratory sense in the distal limbs (Casari et al., 1998; Casari 
and Marconi, 2006, updated 2010; Harding, 1983). Some patients show complicated 
form of HSP, which is characterized by additionally symptoms, such as mental 
retardation, optic atrophy, peripheral neuropathy, ptosis, decreased hearing, amyotrophy 
and ataxia (Casari et al., 1998; Casari and Marconi, 2006, updated 2010). Mitochondrial 
DNA deletion and mitochondrial respiratory chain defects in SPG7 patient muscles 
imply mitochondria dysfunction in the pathogenesis of HSP (Atorino et al., 2003; 
Casari et al., 1998; McDermott et al., 2001; Wedding et al., 2014; Wilkinson et al., 
2004). 
Mutations in AFG3L2 on chromosome 18p11.21 (Banfi et al., 1999; Cagnoli et al., 2006; 
Di Bella et al., 2010), cause two neurological diseases, autosomal dominant 
spinocerebellar ataxia type 28 (SCA28) (Cagnoli et al., 2006; Cagnoli et al., 2010; Di 
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Bella et al., 2010; Edener et al., 2010; Mariotti et al., 2008; Smets et al., 2014; 
Svenstrup et al., 2016; Zuhlke et al., 2015) and recessive spastic ataxia 5 (SPAX5) 
(Pierson et al., 2011). Additionally, two unrelated subjects carrying homozygous 
missense mutation of AFG3L2, have been identified from a cohort of progressive 
myoclonus epilepsy by exome sequencing (Muona et al., 2015). Spinocerebellar ataxia 
(SCA), characterized by progressive gait, stance and limb ataxia, oculomotor 
disturbances, dysarthria, is mostly owing to degeneration of Purkinje cells in the 
cerebellum (Brussino et al., 2011, updated 2013; Di Bella et al., 2010; Schols et al., 
2004). SCA28, one of the most recently characterized forms of SCA, is the first 
autosomal dominant spinocerebellar ataxia shown to be caused by mitochondrial gene 
mutations (Mariotti et al., 2012). The general onset of SCA28 is in young adulthood 
(24.4 ± 14.9 years) with the range from 3 years to 60 years (Brussino et al., 2011, 
updated 2013). Patients show slowly progressive gait disorder, upper limb ataxia, lower 
limb hyperreflexia, dysarthria, nystagmus and ophthalmoparesis (Brussino et al., 2011, 
updated 2013; Edener et al., 2010; Mariotti et al., 2012; Zuhlke et al., 2015). To date, 15 
missense mutations of AFG3L2 have been identified (Cagnoli et al., 2006; Cagnoli et al., 
2010; Di Bella et al., 2010; Lobbe et al., 2014; Svenstrup et al., 2016; Zuhlke et al., 
2015), which represent around 3% of all SCAs and 1.5% of autosomal dominant 
cerebellar ataxias in Europe (Cagnoli et al., 2010). Recently, one partial deletion and 
one frameshift mutations of AFG3L2 also have been shown to cause SCA28 (Musova et 
al., 2014; Smets et al., 2014). Most mutations in the exon 15-16 of AFG3L2 
corresponding the highly conserved proteolytic domain indicate specific substrates 
processing might be critical in the molecular pathology of SCA28 (Cagnoli et al., 2010; 
Di Bella et al., 2010; Lobbe et al., 2014; Svenstrup et al., 2016; Zuhlke et al., 2015). 
Likewise, two reported homozygous mutations of AFG3L2 are also in this mutational 
hotspot exon 15-16 (Muona et al., 2015; Pierson et al., 2011). The two brothers 
identified with AFG3L2 homozygous mutations from a consanguineous family, showed 
early onset SPAX5, which is characterized clinically by lower extremity spasticity, 
progressive myoclonic epilepsy, peripheral neuropathy, dysarthria, ptosis, oculomotor 
apraxia and cerebellar atrophy (Pierson et al., 2011). This phenotype is reminiscent of a 
combined syndrome of HSP and SCA28. The disease course of these two brothers was 
similar, and the younger sibling was more severe and died at the age of 13 years due to 
pneumonia-related complications (Pierson et al., 2011). The newly reported two cases 
carrying homozygous mutations of AFG3L2, known to be unrelated, also displayed 
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severe progressive myoclonus, ataxia and mild cognitive decline (Muona et al., 2015). 
Notably, their phenotype is not as severe as the two brothers’, suggesting clinical 
variability in SPAX5. Loss-of-function mutations in AFG3L2 cause proteolytic 
impairment and mitochondrial respiratory chain deficiency have been implicated in the 
pathogenesis of SCA28 and SPAX5 (Di Bella et al., 2010; Pierson et al., 2011). 
1.2.3 Available murine models of the m-AAA protease 
In order to better unravel the pathogenesis of human diseases associated with mutations 
of SPG7 and AFG3L2, multiple murine models of the m-AAA protease have been 
established. These models show dosage-dependant phenotype, probably owing to the 
fact that AFG3L2 forms both homo- and hetero-hexameric complexes and paraplegin 
only forms hetero-hexameric complex (Koppen et al., 2007). 
Two murine models of SPAX5 have been reported: Afg3l2 null (Afg3l2EMV66/EMV66) 
generated by integrating ecotropic murine leukemia virus insertion 66 (EMV66) within 
intron 14, and a spontaneous mutant carrying a missense mutation in exon 10 (Maltecca 
et al., 2008). Both Afg3l2 null and spontaneous missense mutant mice display a very 
severe neuromuscular syndrome with hindlimb paraparesis one week after birth and 
general die at P16 (Maltecca et al., 2008). Afg3l2 deletion or loss-of-function causes 
mitochondrial morphological alternation and respiratory chain complexes deficit, 
leading to an impairment of axonal development with myelination delay and radial 
growth defect (Kondadi et al., 2014; Maltecca et al., 2008). Notably, in these Afg3l2 
mutant mice, non-neuronal tissues, such as muscle and liver, are not significantly 
affected, indicating that nervous system are solely affected by Afg3l2 deletion or 
mutation (Maltecca et al., 2008). Interestingly, studies from our group provided novel 
insights into pathogenic mechanism of neurodegeneration. We have shown that an 
impairment of mitochondrial ribosome assembly and a decrease of mitochondrial 
translation in the Afg3l2 null mice (Almajan et al., 2012). More recently, in these Afg3l2 
null mice, we have found microtubular network disruption and accumulation of 
hypersphosphorylated tau in the neurons (Kondadi et al., 2014).  
 The murine model haploinsufficient for Afg3l2 (Afg3l2+/EMV66), which represents model 
of SCA28, shows progressive impairment in motor balance and coordination owing to 
Purkinje cell dark degeneration (Martinelli et al., 2009). Mitochondrial respiratory chain 
dysfunction and increased ROS level were previously implicated in the pathology 
  15 
(Martinelli et al., 2009). Moreover, recent data have shown that the ataxic phenotype of 
Afg3l2+/EMV66 mice can be partial restored by reducing Ca2+ influx in Purkinje cells by 
either genetic silencing of the metabotropic glutamate receptor or administration of the 
β-lactam antibiotic ceftriaxone (Maltecca et al., 2015). Thus, mitochondrial Ca2+ 
handling inefficiency is also involved in the pathogenesis of SCA28 and might be a 
potential therapeutic target (Maltecca et al., 2015). 
In comparison with severe developmental phenotype of Afg3l2 null and missense 
mutant mice, Spg7 knockout mice (Spg7-/-) grow normally and show progressive axonal 
degeneration and motor impairment starting from 4 months of age (Ferreirinha et al., 
2004), which models the disease of HSP with loss-of-function mutations in SPG7. 
Interestingly, in the Spg7-/- mice, abnormal mitochondrial morphology occurs before 
initial signs of axonopathy, and followed by axonal swelling with organelle and 
neurofilament accumulation, together, suggesting that primary mitochondrial 
dysfunction and secondary axonal transport defect may lead to corticospinal and 
peripheral axonal swelling and degeneration (Ferreirinha et al., 2004). Interestingly, 
alternative splicing of Spg7 produces a variant of paraplegin in the mouse, which 
localizes to the endoplasmic reticulum, still presents in the Spg7-/- mice. The Spg7-/- 
murine model is therefore an isoform-specific knockout (Mancuso et al., 2012). 
Spg7-/- Afg3l2+/EMV66 double mutant mice display an early-onset severe neurologic 
phenotype characterized by loss of balance, tremor, and ataxia (Martinelli et al., 2009). 
These mice show an acceleration of the axonopathy observed in Spg7-/- mice, and 
prominent Purkinje cell degeneration at earlier age comparing to Afg3l2+/EMV66 mice 
(Martinelli et al., 2009), revealing a genetic interaction between the m-AAA protease 
isoenzymes homo-oligomeric AFG3L2 complex and hetero-oligomeric complex 
composed of paraplegin and AFG3L2 (Martinelli et al., 2009).  
Studies of Afg3l2 conditional murine models provide more insights into the pathogenic 
mechanism. Deletion of Afg3l2 in Purkinje cells in the cerebellum causes mitochondrial 
fragmentation and COX deficiency prior to neurodegeneration, suggesting that 
mitochondrial morphological alternation and respiratory chain complex defect are early 
events in the pathogenic cascades (Almajan et al., 2012). Notably, the number of COX-
deficient cells does not increase with time suggesting that Purkinje cells die shortly after 
displaying this phenotype (Almajan et al., 2012). Similarly, postnatal ablation of Afg3l2 
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in forebrain neurons causes rapidly neuronal death (Kondadi et al., 2014). Interestingly, 
we have identified ERK1/2 and PKA activation and tau hyperphosphorylation in 
Afg3l2-deficient neurons (Kondadi et al., 2014). Thus, together with the finding of tau 
hyperphosphorylation in Afg3l2 null mice, a novel pathogenic mechanism in which tau 
pathology caused by AFG3L2 depletion leads to neurodegenration is proposed 
(Kondadi et al., 2014).  
In summary, aforementioned murine models recapitulate the important 
pathophysiological features of related human diseases. Mechanistically, these mouse 
models show that AFG3L2 influences mitochondrial dynamics, respiration, ROS levels 
and Ca2+ handling, it is therefore essential for neuronal survival (Figure 1.3). Besides, 
different neuronal populations have variable thresholds of susceptibility to the m-AAA 
protease deficiency (Martinelli et al., 2009) and Purkinje cells seem to be the most 
vulnerable cells upon loss of the m-AAA protease. However, the cell-autonomous role 
of the m-AAA protease in other cell types, such as glial cells, has not been extensively 
investigated. Moreover, these studies have not considered that an additional subunit of 
the m-AAA protease, AFG3L1, which is a high homologous to AFG3L2, is present in 
the mouse.  
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Figure 1.3 Pathogenic mechanisms of neurodegeneration caused by m-AAA protease deficiency 
Depletion or mutations of the m-AAA protease subunits cause several pathogenic pathways including 
impaired mitochondrial protein synthesis, accumulation of misfolded proteins, inefficient Ca2+ handling, 
decreased assembly and stability of respiratory chain complexes I and III, reduced mt-DNA, defective 
anterograde transport and disturbed mitochondrial dynamics. Adapted from (Martinelli and Rugarli, 
2010). 
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1.3 Myelinating cells 
In vertebrates, myelinating cells are highly specialized glial cells that wrap axons with 
multi-layered myelin for rapid impulse propagation and axonal integrity (Nave and 
Trapp, 2008; Simons and Trotter, 2007). The myelin sheath, a specialized cell 
membrane, is formed by oligodendrocytes in the central nervous system (CNS) and 
Schwann cells in the peripheral nervous system (PNS) (Nave and Trapp, 2008; Simons 
and Trotter, 2007). The myelin membrane is composed of unique lipids and proteins 
that have to be assembled temporally and spatially (Figure 1.4) (Aggarwal et al., 2011; 
Baumann and Pham-Dinh, 2001; Simons and Trotter, 2007). A recent study has shown 
that myelin growth occurs by consecutive wrapping of the inner tongue around the axon 
and simultaneous lateral extension of newly formed myelin layers (Snaidero et al., 
2014). Neuronal signals regulate myelinating cell development and myelin assembly 
(Nave and Trapp, 2008; Simons and Trajkovic, 2006); in turn, deficiency of myelin 
proteins or myelinating cells causes axonal demyelination and/or degeneration (Dewar 
et al., 2003; Lee et al., 2012; Nave et al., 2007; Nave and Trapp, 2008; Olmos-Serrano 
et al., 2016; Trapp and Nave, 2008; Viader et al., 2011).  
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Figure 1.4 Schematic representation of myelinating cells, myelin structure and components.  
While Schwann cells in the PNS only myelinate one axon, oligodendrocytes in the CNS are able to wrap 
several axons. The compact myelin is formed by the apposition of the external surfaces of the myelinating 
cell membrane, forming the “double intraperiod line”; the apposition of the internal surfaces followed by 
the extrusion of the cytoplasm, forming the “major dense line.” The lipid composition of myelin bilayer is 
asymmetric. Some major myelin proteins are indicated and classified according to the expression region. 
Adapted from (Aggarwal et al., 2011; Baumann and Pham-Dinh, 2001). 
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1.3.1 Oligodendrocytes 
During the development of CNS, oligodendrogenesis takes place in multiple foci. In the 
spinal cord, most oligodendrocyte precursor cells (OPC) arise from the ventral 
progenitor domain starting from E12.5, then migrate laterally and dorsally to occupy the 
whole spinal cord after specification (Fancy et al., 2011). Besides, commencing ~E15.5, 
dorsal-derived OPC contribute to 20-30% of total OPC (Fancy et al., 2011; Vallstedt et 
al., 2005). In the forebrain, multiple waves of OPC production and migration occur 
from embryonic to postnatal stages (El Waly et al., 2014; Fancy et al., 2011).  At E12.5, 
the first wave of OPC production originates in the medial ganglionic eminence and 
anterior entopeduncular area in the ventral brain (Kessaris et al., 2006). However, the 
majority of adult oligodendrocytes in mouse arise from the second and third wave of 
OPCs emanating from the lateral and/or caudal ganglionic eminences at E15.5 and from 
the cortex after birth, respectively (El Waly et al., 2014; Kessaris et al., 2006). 
Interestingly, genetical ablation of one population of oligodendrocytes in restricted 
areas in the CNS, triggers adjacent populations rapid migration and proliferation to 
maintain their normal density in adult mouse (Hughes et al., 2013; Kessaris et al., 2006).  
While some OPC are reserved for myelin regeneration, others are specified and 
differentiate to myelinating oligodendrocytes (Figure 1.5) (Fancy et al., 2011). 
Oligodendrocytes are capable to myelinate several axons selectively with diameter 
above 0.2 µm (Simons and Trajkovic, 2006; Waxman and Sims, 1984). The process of 
oligodendrocyte maturation and myelination is very complicated, because it is highly 
coordinated with neurons/axons, and numerous signal pathways and regulatory factors 
are involved (Bradl and Lassmann, 2010; Fancy et al., 2011) (Figure 1.5).  
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Figure 1.5 Schematic illustrating oligodendrocyte development and differentiation 
In the spinal cord, oligodendrocyte precursor cells (OPC) are derived from the ventral progenitor domain, 
which also produces motor neurons. Oligodendrocytes express specific antigenic markers and follow a 
stepwise morphological transformation during development and differentiation. Solid black arrows 
indicate oligodendrocyte-lineage transitions that are dependent on specific transcription factors, and 
coloured gradient bars represent predicted temporal expression pattern of essential factors or regulators 
(Fancy et al., 2011). 
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1.3.2 Schwann cells 
At early embryonic developmental stage of peripheral nerves, neural crest cells give rise 
to Schwann cell precursors (SCP) that are found among the axons of nascent nerves, 
and SCP develop into immature Schwann cells before birth (Jessen and Mirsky, 2005). 
Postnatal immature Schwann cells differentiate into either myelinating Schwann cells or 
non-myelinating Schwann cells (Figure 1.6) (Jessen and Mirsky, 2005; Woodhoo and 
Sommer, 2008). Schwann cells produce basal lamina and start radial sorting of 1:1 
relationship (one myelinating Schwann cell ensheaths one axon) with large-calibre 
axons (diameter > ~ 1 µm) (Jessen and Mirsky, 2005; Simons and Trotter, 2007). 
Unmyelinated smaller axons (also known as C-fibre axons) forming Remak bundles are 
wrapped and segregated by non-myelinating Schwann cells. Multiple molecules and 
factors have been implicated in the regulation of Schwann cell development and 
myelination (Jessen and Mirsky, 2005). For instance, axon-derived signaling molecule 
Neuregulin-1 (NRG1), a EGF-like ligand for the ErbB family of tyrosine kinase 
receptors (Garratt et al., 2000; Van Raamsdonk and Deo, 2013), promotes Schwann cell 
lineage survival and development, and regulates myelin sheath thickness (Brinkmann et 
al., 2008; Garratt et al., 2000; Grinspan et al., 1996; Michailov et al., 2004; Taveggia et 
al., 2005). 
One fascinating aspect of SCP is bipotentiality, not only having glial fate, but also 
giving rise to melanocytes that originate from neural crest cells as SCP. In the mouse at 
E10.5, shortly after neural crest delamination, the first wave of melanocyte precursor-
melanoblasts migrate dorsolaterally between the dermamyotome and eventually reach 
the destination of the basal layer of the epidermis and the hair follicles (Adameyko et al., 
2009; Erickson, 1993). At around E12.5, a second pathway, melanoblasts differentiated 
from SCP migrate ventrally along the nerves and contribute to a large number of 
melanocytes in the limbs, in the dorsal and lateral body wall (Adameyko et al., 2009; 
Van Raamsdonk and Deo, 2013). However, the role of SCP in formation of 
melanocytes in the adult or age-related hair greying remains elusive (Adameyko et al., 
2009). 
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Figure 1.6 Development of Schwann cell lineage in mouse.  
Schwann cells originate from the neural crest cells at early embryonic development. Markers of different 
developmental Schwann cell lineages are in coloured frames. The same colour means shared antigen 
expression. Dashed arrows indicate the reversible transformation of mature myelinating and 
nonmyelinating Schwann cells to immature Schwann cells. Adapted from (Jessen and Mirsky, 2005). 
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1.3.3 Pathology of myelin-forming cells 
One of the main functions of myelinating cells is to produce multi-layered membrane 
structure of myelin, which insulates the axon and clusters sodium channels into the 
nodes of Ranvier, thus enables the action potential to conduct from one node to the 
other (Aggarwal et al., 2011). During the peak of myelination, oligodendrocytes 
elaborate several times the cell weight in membrane per day and ultimately produce 
membranes up to 100 times the weight of the cell body (Bradl and Lassmann, 2010), 
and the process of myelin synthesis and assembly requires a great amount of energy. 
Assuming that all basic components for lipid and proteins were available locally, the 
minimum energetic cost of myelin synthesis would be 3.30 x 1023 ATP molecules per 
gram myelin in the CNS (Harris and Attwell, 2012). Oligodendrocytes have very high 
metabolic rates to produce ATP, and this process also generates toxic by-product ROS 
(Bradl and Lassmann, 2010). Additionally, oligodendrocytes contain high amount of 
myelin synthetic enzyme cofactor-iron (Thorburne and Juurlink, 1996), which can 
provoke free radical formation and lipid peroxidation under adverse conditions (Bradl 
and Lassmann, 2010; Braughler et al., 1986; Juurlink, 1997). Given the fact that 
oligodendrocytes have low concentration of ROS scavenger glutathione and the 
susceptibility to inflammatory cytokines exposure, hypoxia, ischemia and pathogenic 
autoimmune, these cells are particularly vulnerable under pathological conditions (Bradl 
and Lassmann, 2010; Dewar et al., 2003; Thorburne and Juurlink, 1996).  
In addition to myelin sheath formation, myelinating cells also metabolically support 
axonal survival (Funfschilling et al., 2012; Lee et al., 2012). Oligodendrocytes highly 
express monocarboxylate transporter 1 (MCT1) to transport glycolysis product lactate 
to axons (Funfschilling et al., 2012; Lee et al., 2012; Rinholm et al., 2011), and MCT1 
deficiency leads to axonal degeneration (Lee et al., 2012). Importantly, several human 
neurodegenerative disorders, for instance, Multiple Sclerosis (MS), inherited 
leukodystrophies and Charcot-Marie-Tooth disease (CMT), have been implicated with 
myelinating cell pathology and myelin defects (Nave, 2010). Primary axonal 
degeneration occurs in some forms of demyelinating diseases, but secondary axonal 
degeneration is believed be the major cause of persistent neurological impairments 
(Table 1.1) (Nave, 2010).  
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Table 1.1 Human diseases associated with myelin defects and secondary axonal degeneration 
Diseases  Frequency and 
causes  
Glia and myelin 
pathology  
Secondary 
axonal loss 
 Animal models  
Multiple 
Sclerosis 
(MS)  
• Relatively 
common 
autoimmune 
disease  
• Primary cause 
unknown  
• Viral origin and 
genetic risk factors 
suggested  
• CNS-specific disease  
• Inflammatory lesions 
in white-matter tracts 
cause oligodendrocyte 
death, extensive 
demyelination and 
macroscopic plaques  
• Axonal 
swellings and 
transections in 
white- and grey-
matter lesions  
• Axon loss 
associated with 
permanent 
disability at later 
disease stages  
• EAE for 
modelling 
autoimmunity 
against myelin 
epitopes and the 
inflammatory phase 
of MS  
Inherited 
leukodyst
rophies  
• Very rare genetic 
disorders  
• Several single-
gene defects 
identified, such as 
in PLP1 (for PMD), 
GJC2 (for PMLD), 
ABCD1 (for 
adrenoleukodystrop
hy) and ASA (for 
metachromatic 
leukodystrophy)  
• Defects of terminal 
oligodendrocyte 
differentiation and 
myelin formation  
• Defects of myelin 
maintenance with 
demyelination (also 
secondary 
inflammation in 
adrenoleukodystroph)  
• Perturbation of 
axonal transport 
followed by 
Wallerian 
degeneration  
• Purely axonal 
forms of 
leukodystrophies
: SPG2 
(associated with 
PLP1 defects) 
and 
adrenomyelo- 
neuropathy 
(associated with 
ABCD1 defects)  
• Rodents with 
mutations 
corresponding to 
the human disease 
gene, such as a Plp1 
point mutation or 
Plp1 
overexpression (for 
PMD), Plp1 
knockout (for 
SPG2) and Abcd1 
knockout (for 
adrenomyeloneuro-
path)  
Inherited 
demyelina
ting 
neuropat
hies  
• Rare genetic 
disorders, such as 
CMT  
• Many disease 
genes identified, 
such as PMP22 (for 
CMT1A), P0 (for 
CMT1B) and GJB1 
(for X-linked CMT)  
• Defects of Schwann 
cell differentiation and 
peripheral myelination, 
or myelin maintenance 
• Segmental 
demyelination with 
formation of ‘onion 
bulbs’  
• Slowly 
progressive and 
length-dependent 
axon loss 
causing 
denervation, 
sensory deficits 
and muscle 
weakness — the 
clinical 
hallmarks of 
CMT  
• Rodents with 
mutations in or 
overexpression of 
genes 
corresponding to 
human disease 
genes, such as 
Pmp22 (for 
CMT1A), Mpz (for 
CMT1B) and Gjb1 
(for X-linked CMT)  
ABCD1, ABC binding cassette family D member 1; ASA, aryl sulphatase A; EAE, Experimental allergic 
encephalomyelitis; GJB1, gap junction protein β1; GJC2, gap junction protein γ2 (also known as GJA12 
and CX47); PLP1, proteolipid protein 1; PMD, Pelizaeus–Merzbacher disease; PMLD, Pelizaeus–
Merzbacher-like disease. This table is from (Nave, 2010). 
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1.3.4 The role of mitochondria in myelinating cells 
Mitochondrial dysfunction has been implicated in inflammatory demyelinating diseases 
(Mahad et al., 2008; Mahad et al., 2015; Popescu and Lucchinetti, 2012; Witte et al., 
2014), and axonal demyelination is associated with several mitochondrial diseases, such 
as autosomal dominant optic atrophy, caused by OPA1 mutations (Alexander et al., 
2000; Johnston et al., 1979); dominant CMT type 2 disease, caused by MFN2 mutations 
(Niemann et al., 2006; Zuchner et al., 2004); inherited Leber’s hereditary optic 
neuropathy (LHON), caused by mitochondrial DNA mutations (Kovacs et al., 2005). 
Therefore, more insights into the function of mitochondria in myelinating cells may be 
beneficial to understand the pathogenic cascades of axonal demyelination and 
neurodegeneration. 
The roles of mitochondria in myelinating cells are distinct and depend on the 
developmental stages. In vitro studies have demonstrated that oligodendrocyte 
precursors are more resistant to mitochondrial respiratory chain complex inhibitors; in 
contrast, differentiated and mature oligodendrocytes are much more sensitive 
mitochondrial respiratory defects (Schoenfeld et al., 2010; Ziabreva et al., 2010). 
Inhibition of mitochondrial complex I or complex IV impairs differentiated 
oligodendrocyte process formation and myelin protein expression (Schoenfeld et al., 
2010; Ziabreva et al., 2010), despite the fact that the viability of oligodendrocytes under 
this circumstances needs further investigation. Moreover, differentiated 
oligodendrocytes upregulate globally the transcripts of mitochondrial genes to provide 
energy and metabolites for myelin synthesis (Schoenfeld et al., 2010). Nevertheless, 
limited in vivo studies have shown that mitochondrial respiratory deficiency does not 
affect the survival of Schwann cells nor oligodendrocytes, and an energy metabolism 
adaptation is proposed (Funfschilling et al., 2012; Viader et al., 2011). Interestingly, 
Schwann cell-specific deletion of mitochondrial transcription factor A (Tfam), which is 
essential for mitochondrial DNA maintenance and biogenesis (Larsson et al., 1998), 
activates heme-regulated inhibitor kinase and induces an integrated stress response 
maladaptation, thereby causes lipid metabolism shift from fatty acid synthesis toward 
oxidation and subsequently leads to progressive demyelination (Viader et al., 2011; 
Viader et al., 2013). Cox10, encodes a heme A farnesyl transferase and is an assembly 
factor of COX (Antonicka et al., 2003; Nobrega et al., 1990), depletion of which using 
mice constitutively express Cre recombinase in Schwann cells or in both Schwann cells 
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and oligodendrocytes leads to severe neuropathy (Funfschilling et al., 2012). By 
contrast, using an inducible PLP1-CreERT2 line to delete Cox10 in oligodendrocytes in 
adult mice does not cause any phenotype. This is because when myelination is complete, 
mature oligodendrocytes utilize glycolysis to supply lactate for the maintenance of 
myelin and axonal integrity (Funfschilling et al., 2012). Thus, mitochondria play crucial 
roles for myelinating cell differentiation and myelination, but these glial cells do not 
rely on mitochondria to produce ATP for the survival of these cells or axonal energy 
requirement in the adulthood.  
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2 Aim of the thesis 
Mitochondria are pivotal organelles to support cellular energy requirement, Ca2+ 
homeostasis, metabolism, and apoptosis regulation, especially in polarized and aerobic 
neurons. Mitoproteases degrade misfolded, non-assembled or damaged proteins as part 
of quality control surveillance system (Martinelli and Rugarli, 2010; Quiros et al., 2015; 
Rugarli and Langer, 2012). Moreover, mitoproteases perform highly regulated 
proteolytic reactions, such as processing specific substrates that are crucial for 
mitochondrial biogenesis, translation, dynamics, mitophagy and apoptosis. 
Mitoproteases therefore emerge as essential regulators of mitochondrial function and 
quality control at molecular, organellar and cellular levels (Anand et al., 2013; Quiros et 
al., 2015).  
One of the known mitoproteases is the m-AAA protease, localized in the mitochondrial 
inner membrane, and composed of hexameric complexes formed by AFG3L2 and 
paraplegin in humans (Koppen et al., 2007). Mutations of AFG3L2 and paraplegin have 
been associated with three neurodegenerative diseases SCA28, SPAX5 and HSP 
(Rugarli and Langer, 2012). Previous studies have shown that m-AAA protease 
deficiency causes mitochondrial respiratory deficits, morphological alterations, 
anterograde transport impairment, and calcium handling failure (Almajan et al., 2012; 
Atorino et al., 2003; Ehses et al., 2009; Ferreirinha et al., 2004; Kondadi et al., 2014; 
Maltecca et al., 2008; Maltecca et al., 2015; Maltecca et al., 2012; Martinelli et al., 
2009). However, the pathogenic cascades of neurodegenerative diseases linked to m-
AAA protease mutations remain elusive. In addition, the cell-autonomous role of the m-
AAA protease is poorly understood. Therefore, in this study, we have these two aims: 
1. Investigation the pathogenic cascades of AFG3L2 deficiency in neurodegeneration 
Lack of AFG3L2 leads to mitochondrial fragmentation and dysfunction, and 
subsequently neuronal death, however, the pathogenic mechanism is not very clear. 
Since Afg3l2 full-body knockout mice show phenotypic complexity and early death, we 
generated forebrain neuron-specific mice in which Afg3l2 is depleted postnatally. We 
studied these two murine models to investigate the molecular alterations or signaling 
pathways triggered by Afg3l2 deletion. 
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2. Elucidation the role of the m-AAA protease in myelinating cells. 
Oligodendrocytes and Schwann cells produce myelin sheaths to wrap axons, thus 
facilitating the efficient and rapid propagation of nerve impulse (Nave and Trapp, 2008), 
and metabolically support axonal long-term survival (Funfschilling et al., 2012). How 
mitochondrial dysfunction in glial cells contributes to neurodegenerative diseases is 
largely unknown. Moreover, the m-AAA protease plays key roles in multiple aspects of 
mitochondria, but all published m-AAA protease related mouse studies have either used 
constitutive mutant models or focused on the role of AFG3L2 in neurons. Whether 
AFG3L2 deficiency in glial cells leads to mitochondrial dysfunction and contributes to 
neurodegenerative phenotype has not been explored. To this end, we deleted Afg3l2 in 
myelinating cells by crossing tamoxifen inducible PLP1-CreERT mice (Doerflinger et 
al., 2003) with conditional Afg3l2fl/fl mice (Almajan et al., 2012). Moreover, considering 
potential compensatory effect of AFG3L1 that is also expressed in the mouse, we 
depleted the whole m-AAA protease in myelinating cells by crossing PLP1-
CreERT/Afg3l2fl/fl mice with unpublished Afg3l1 full-body knockout mice, which do not 
show evident neurological phenotype. In addition, a reporter ROSA26+/SmY line (Sterky 
et al., 2011) was used to examine mitochondrial morphology and the fate of targeted 
cells. With these murine models, we explored possible OXPHOS-independent function 
of the m-AAA protease in myelinating cells, which in comparison with neurons, may 
survive by glycolysis. 
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3 Material and methods 
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3.1 Animal experiments 
All animals procedures were conducted in accordance with European, national and 
institutional guidelines and were approved by local authorities. Unless stated otherwise, 
animals were hosted in the CECAD in vivo research facility with 12:12 light/dark cycle. 
Daily care of animals was performed by qualified caretakers in compliance with 
institutional animal welfare protocols. Mice of both female and male were used in this 
study.  
3.1.1 Mouse breedings 
Single transgenic mouse strains: 
1. Afg3l2+/EMV66 mice were generated originally in FVB genetic background (Maltecca 
et al., 2008). Afg3l2EMV66/EMV66 (L2 KO) mice were produced by mating 
Afg3l2+/EMV66 (pure FVB background) mice with Afg3l2+/EMV66 (50% FVB + 50% 
C57BL/6) mice (Figure 3.1). 
 
Figure 3.1 L2 KO mice were obtained on a mixed FVB-C57BL/6 background. 
2. The generation of CamkIIα-Cre mice was as previously described (Minichiello et al., 
1999). Starting from P20, Cre recombinase is expressed in neurons in the forebrain 
including the neocortex, the hippocampus, and the striatum, but it is not expressed 
in the cerebellum (Merkwirth et al., 2012; Minichiello et al., 1999). 
FVB
Afg3l2+/EMV66
FVB
Afg3l2+/EMV66
Afg3l2+/EMV66
 Afg3l2EMV66/EMV66 (L2 KO)
X
C57BL/6
WT
50% FVB and 50% C57BL/6
75% FVB and 25% C57BL/6
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3. PLP1-CreERT, a tamoxifen inducible mouse line, in which the expression of Cre 
recombinase and a mutated ligand-binding domain of the human estrogen receptor 
(CreERT) is under the transcriptional control of the regulatory sequences of the 
gene encoding myelin proteolipid protein 1 (PLP1) (Doerflinger et al., 2003).  
PLP1-CreERT mice were purchased from Jackson Laboratory. 
4. Conditional Afg3l2floxed/floxed (Afg3l2fl/fl) mice carrying two LoxP sites flanking exons 
4 and 5 of Afg3l2 gene were previously described (Almajan et al., 2012). 
5. ROSA26+/SmY mice carrying a lox-flanked stop cassette placed upstream of the 
mitochondrial targeting sequence and YFP transgene were previously reported 
(Sterky et al., 2011). 
6. Afg3l1-/- mice were commercially generated by deletion of exon 2 and 3 in C57BL/6 
background by TaconicArtemis GmbH. 
Generation of mixed lines: 
1. CamkIIα-Cre/ Afg3l2fl/fl 
Mice from CamkIIα-Cre line were crossed to Afg3l2fl/fl mice to produce conditional 
forebrain neuron-specifc Afg3l2 knockout mice (CamkIIα-Crewt/tg/Afg3l2fl/fl, referred to 
as L2NKO). Littermates with the genotype CamkIIα-Crewt/wt/Afg3l2fl/fl or CamkIIα-
Crewt/wt/Afg3l2wt/fl were used as controls. This line was maintained by Anne Korwitz 
(Thomas Langer group) in the animal facility in institute for Genetics, University of 
Cologne. 
2. PLP1-CreERT/ROSA26+/SmY 
PLP1-CreERT mice were mated with ROSA26+/SmY mice to examine recombination 
efficiency and the fate of targeted cells. 
3. PLP1-CreERT/Afg3l2fl/fl 
PLP1-CreERT mice were crossed with Afg3l2fl/fl mice to produce myelinating cells-
specific Afg3l2 knockout mice (PLP1-Crewt/tg/Afg3l2fl/fl, referred to as L2MC-KO) upon 
tamoxifen administration. The littermates with the genotype PLP1-Crewt/wt/Afg3l2fl/fl 
referred to as L2fl/fl were also injected with tamoxifen and employed as controls. 
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4. PLP1-CreERT/Afg3l2fl/fl/ROSA26+/SmY 
PLP1-CreERT/Afg3l2fl/fl mice were mated with ROSA26+/SmY mice (Sterky et al., 2011) 
to visualize mitochondrial morphology in Afg3l2 deficient myelinating cells. 
5. PLP1-CreERT/Afg3l2fl/fl/Afg3l1-/- 
PLP1-CreERT/Afg3l2fl/fl mice were bred with Afg3l1-/- mice to completely delete the m-
AAA protease in myelinating cells. Mice with genotype of PLP1-
Crewt/tg/Afg3l2fl/fl/Afg3l1-/- were referred to as DKO. The control littermates with 
genotype PLP1-Crewt/wt/Afg3l2fl/fl/Afg3l1-/- were referred to as CTRL. All experimental 
CTRL and DKO were injected with tamoxifen.  
6. PLP1-CreERT/Afg3l2fl/fl/ Afg3l1-/-/ROSA26+/SmY 
PLP1-CreERT/Afg3l2fl/fl/Afg3l1-/- mice were further crossed to ROSA26+/SmY line to 
visualize mitochondrial morphology in myelinating cells upon deletion of the whole m-
AAA protease. 
3.1.2 Genotyping 
Tails were incubated in lysis buffer (50 mM Tris-HCl pH 8, 100 mM NaCl, 100 mM 
EDTA pH 8, 0.5% SDS, and 0.9 mg/ml proteinase K) at 55°C overnight. After 
centrifugation at 10,000 g for 10 minutes at room temperature, the supernatant was 
collected in a new tube, and the DNA was precipitated with 100% ethanol, and washed 
with 70% ethanol. The DNA was resuspended in TE buffer (10 mM Tris-HCl, 1 mM 
EDTA, pH 8). EmeraldAmp MAX PCR Master Mix (TaKaRa) was applied to set up 
polymerase chain reaction (PCR) according to the user guide with minor modification 
that the volume of each reaction was reduced to 15 µl. The primers for PCR are listed 
below (Table 3.1). Final PCR products were loaded onto 1% or 1.5% agarose gels.  
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Table 3.1 Primers for genotyping 
Locus Primer name Sequence (5’-3’) Amplicon Size 
Afg3l2 
 wt FW GGAACTGACCATATCTGGTTGTCTG 
wt 258 bp 
ko 390 bp 
ko FW CCAGAAACTGTCTCAAGGTTCC 
 wt/ko RV TGGATTCTGCACATCTCTTAACCC 
Cre 
FW TCCAATTTACTGACCGTACAC 
tg 750 bp 
RV GTTATTCGGATCATCAGCTAC 
Afg3l2 
wt/fl FW TTGGTTTTGTATGTGTTAGGTCAG wt 387 bp 
fl 506 bp wt/fl RV GCCTGCACAGCTCCATGAT 
Afg3l1 
wt/ko FW GCATTGCACAGTCATTTCAGG 
wt 272 bp 
ko 509 bp 
wt RV GCCGTGGGTAATGTTTGTTCC 
ko RV TGGACAGGGCATTATGATGC 
ROSA26 
mt-YFP1 AAAGTCGCTCTGAGTTGTTAT 
 tg 250 bp 
wt 583 bp 
mt-YFP2 GCGAAGAGTTTGTCCTCAACC 
mt-YFP3 GGAGCGGGAGAAATGGATATG 
Abbreviation: FW, forward primer; RV, reverse primer; tg, transgene band.  
3.1.3 Tamoxifen administration 
Tamoxifen (T5648, Sigma) was dissolved in a corn oil/ethanol (9:1) mixture at a final 
concentration of 10 mg/ml. For pregnant female (~E15.5), 1 mg tamoxifen per 10 g 
body weight was administered by gavage once. For 4-week-old (P28-30) mice, 1 mg 
tamoxifen was administered by intraperitoneal injection once a day for 5 consecutive 
days. 
3.1.4 Behavioral tests 
In order to test motor ability and coordination of mice, rotarod test and beam-walking 
test were performed. For the rotarod test, mice were placed on an accelerating rotating 
(TSE systems) rod with a starting speed of 4 rpm and a constant acceleration of 7.2 
rpm/min and the latency time to fall was recorded for each mouse up to a maximum of 
300 seconds. Three tests were performed each day for 3 consecutive days, and mice 
were allowed to rest for 15 minutes after each test. Steffen Hermans assisted with the 
rotarod test. 
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In the beam-walking test, mice have to stay upright and walk through an elevated 
narrow beam to reach a safety dark box, and it is more sensitive to detect subtle motor 
impairment in comparison with the rotarod test (Luong et al., 2011; Stanley et al., 2005). 
In this test, 2 days of training and 1 day of testing were performed. In all 3 consecutive 
days, mice were trained to walk sequentially across a 3 cm beam and a 1 cm beam, 
which were elevated by a 30 cm metal support. On the third day, the performance of 
each mouse while acrossing the 1 cm beam was filmed and the number of foot slips was 
quantified. 
In both behavioral tests, all available aged-matched mice were employed during the 
testing period, and no mouse was discriminated.  
3.1.5 Fat content measurement 
The body composition of mice was examined with quantitative magnetic resonance 
analyser (Bruker Minispec, MQ10). 
3.2 Tissue Collection 
Mice were anaesthetized with ketamine/xylazine (10 mg/100 mg per kg of body weight), 
and perfused transcardially first with PBS followed by 4% paraformaldehyde (PFA) in 
PBS (pH 7.4). Brain, spinal cord, and the peripheral nerves were then dissected and post 
fixed in 4% PFA for histology and immunofluorescence or in 2% glutaraldehyde in 0.12 
M phosphate buffer for electron microscopy. The skin was collected before perfusion 
and immersed in 4% PFA for 2-4 h at 4°C, then cryo-protected in 15% sucrose for 2 h 
followed by incubation in 30% sucrose overnight. For western blot analyses and 
TUNEL assay, mice were sacrificed by cervical dislocation and respective tissues were 
collected for analysis. 
3.3 Histology and immunohistochemistry 
3.3.1 Slice preparation 
Vibratome sectioning: 
Postfixed brain and spinal cord were embedded in 6% agar, and cut at a thickness of 30 
µm with a vibratome (VS1000, Leica). Free-floating sections were stored in 0.12 M 
phosphate buffer supplemented with 0.01% sodium azide at 4°C. 
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Paraffin sectioning: 
Following dehydration in gradient ethanol (70% to 100%) and xylene, the skin was 
embedded in paraffin and 5 µm thick sections were cut with a microtome (RM2255, 
Leica). 
Frozen sectioning: 
Fresh brain or PFA post-fixed skin were embedded in OCT (Tissue-Tek), frozen on dry 
ice and stored at -80°C till use. Samples were equilibrated to cutting temperature (-20°C 
to -25°C) 20 min in advance, and 7 or 10 µm thick sections were cut using a cryostat 
(CM1850, Leica). 
3.3.2 Immunostaining on vibratome sections 
Free-floating sections were post-fixed in 4% PFA or in methanol for 30 min, and rinsed 
in PBS. Alternatively, sections were washed in 1% Triton X-100 for 30 min at room 
temperature. Sections were then blocked in 0.4% Triton X-100 in 10% goat serum for 1 
h at room temperature, and incubated with primary antibodies (Table 3.2) diluted in 5% 
goat serum overnight at 4°C. After washing with PBS, sections were incubated with the 
appropriate secondary antibodies (Table 3.3) for 2 h at room temperature. Sections were 
washed 3 times with PBS (if necessary, to counterstain the nuclei, DAPI (1:2000, stock 
1 mg/ml, Sigma) was added in PBS during the second wash), and mounted with 
Flurosave medium (345789, Calbiochem).  
3.3.3 Immunostaining on paraffin sections 
Following deparaffinization with xylene and gradient ethanol  (100% to 50%), slices 
were rinsed with water and boiled in 0.1 M citrate buffer (pH 6) to unmask epitopes. 
Slices were quickly washed in PBS, and then permeabilized and blocked in 0.4% Triton 
X-100 in 10% goat serum for 1 h at room temperature. Slices were incubated with 
primary antibody (Table 3.2) overnight at 4°C. After washing, slices were incubated 
with secondary antibody (Table 3.3) for 2 h at room temperature, were washed in PBS, 
and mounted with Flurosave medium. When it was required, DAPI was used for 
counterstaining. 
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Table 3.2 Primary antibodies for immunostaining  
Antibody Section preparation Company  Dilution 
APC* Vibratome #OP80, Calbiochem 1:400 
COX1 Vibratome #459600, Invitrogen 1:1000 
Cytochrome c Vibratome #556432, BD Phamingen 1:1000 
GFAP Vibratome #3670, Cell signaling 1:500 
GFAP Vibratome #Z0334, Dako 1:2000 
GFP Vibratome #ab6556, Abcam 1:1000 
IBA1 Vibratome #019-19741, Wako 1:2000 
c-KIT  Paraffin #553352, BD Pharmingen 1:1000 
MBP Vibratome #SMI-94R, Covance 1:1000 
Olig2 Vibratome #AB9610, Millipore 1:500 
S100 Vibratome #Z0311, Dako 1:1000 
* APC antibody worked better when the sections were washed in 1% triton X-100, without methanol 
fixation. For other antibodies for vibratome sections, both treatments worked similarly. 
Table 3.3 Secondary antibodies for immunostaining 
Antibody Company  Dilution 
Anti-mouse Alexa Fluor 488 A-11029, Molecular Probes 1:1000 
Anti-mouse Alexa Fluor 546 A-21143, Molecular Probes 1:1000 
Anti-rabbit Alexa Fluor 488 A-11034, Molecular Probes 1:1000 
Anti-rabbit Alexa Fluor 546 A-11035, Molecular Probes 1:1000 
Anti-rabbit Alexa Fluor 594 A-21207, Molecular Probes 1:1000 
Anti-rat Alexa Fluor 488 A-11001, Molecular Probes 1:1000 
 
3.3.4 Nissl staining 
Vibratome sections were cleaned by removing surrounding agar, and mounted onto 
slides in Cromalin solution (0.1% gelatine, 0.02% potassium chromium sulphate).  The 
slides were allowed to air-dry for 10-20 min at room temperature, then they were 
immersed in Nissl solution (36 mM Sodium hydroxide, 0.24% acetic acid, 0.25% 
thionine acetate) for 30-45 sec. The slides were washed in water several times, 
dehydrated in gradient ethanol (50% to 100%) and xylene, and mounted with Eukitt 
mounting medium. 
3.3.5 Gallyas staining 
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Gallyas staining was carried out as previously described (Pistorio et al., 2006). Briefly, 
free-floating sections were fixed in 10% formalin for 1 day up to several weeks, then 
immersed in 2:1 pyridine/acetic anhydride for 30 min. After washing in gradient 
pyridine (80% to 20%) and water, sections were immersed in freshly prepared 
ammoniacal silver nitrate solution (10 mg ammonium nitrate, 10 mg silver nitrate and 
30 µl 4% NaOH in 10 ml Millipore H2O) for 45 min. Afterwards, sections were washed 
3 times in 0.5% acetic acid for total of 10 min, and transferred into fresh 10% formalin. 
After at least one day of fixation, sectioned were washed 2 times in 0.5% acetic acid, 
and developed in fresh developer (2.5% sodium carbonate, 0.1% ammonium nitrate, 
0.1% silver nitrate, 0.01% PFA) for 30-60 min. Finally, sections were washed with 1% 
acetic acid and water. In case of over exposure or strong background, sections were 
immersed in 0.1% potassium ferricyanide to increase contrast. 
3.3.6 Haematoxylin and eosin staining 
Paraffin slices were deparaffinized and rehydrated, and stained with Mayer’s 
Haematoxylin solution (MHS32, Sigma) for 4 min. After washing in water, slices were 
stained in Eosin Y-solution 0.5% aqueous (1098441000, Millipore) for 20 sec, washed 
in water, dehydrated in gradient (75% to 100%) ethanol and xylene, and mounted with 
Eukitt medium. 
3.3.7 TUNEL assay 
To detect TUNEL positive (+) cells, the In Situ Apoptosis assay (S7101, Millipore) was 
applied on cryostat sections according to the manufacturer’s manual. Briefly, frozen 
sections were fixed in 1% PFA for 10 min at room temperature. After washing in PBS, 
sections were post-fixed and permeabilized in 2:1 ethanol/acetic acid for 10 min at -
20°C. Sections were washed in PBS, and endogenous peroxidase was quenched by 3% 
H2O2 in PBS for 5 min. Sections were incubated shortly with equilibration buffer, and 
then incubated with working strength TdT enzyme in a humidified chamber for 1 hour 
at 37°C. Afterwards, stop/wash buffer was applied for 10 min at room temperature. 
Sections were washed in PBS, and then incubated with anti-digoxigenin conjugate for 
30 min at room temperature. After washing with PBS, sections were developed with 
peroxidase substrate for 5-10 min. Sections were washed in water, and dehydrated in 
ethanol and xylene, and then mounted with Eukitt mounting medium. Positive control 
sample was treated with 0.1-1 µg/mL Deoxyribonuclease I (DNase I, D7291, Sigma) in 
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DNase buffer (30 mM Tris-HCl pH 7.2, 4 mM MgCl2, 0.1 mM DTT) for 10 min at 
room temperature. For negative control, water or equilibration buffer was used to 
substitute working strength TdT enzyme. 
The number of TUNEL+ cells within the corpus callosum was quantified manually. 2-3 
sections from each mouse and 4 mice per group were used for quantification. 
3.4 Microscopy 
3.4.1 Light microscopy 
If not stated otherwise, fluorescent images or bright-filed images were acquired with an 
Axio-Imager M2 microscope equipped with Apotome 2 (Zeiss). When specified, 
confocal images were captured with a gSTED super-resolution and confocal microscope 
with HyD detector (TCS SP 8, Leica), and Huygens deconvolution software was 
applied. For Gallyas staining, Hematoxylin and eosin staining, entire sections were 
scanned with a slide scanner (SCN400, Leica), and regions of interest are shown in 
related figures. 
3.4.2 Electron microscopy 
The corpus callosum and the lumbar spinal cord were post-fixed in 2% glutaraldehyde 
(Sigma) in 0.12 M phosphate buffer at 4°C, and a small piece from each sample was 
prepared and immersed in fresh 2% glutaraldehyde one day before embedding. Small 
pieces of tissues were treated in 1% osmium tetroxide (Sigma) for 1-4 h. After 
dehydration with gradient ethanol (50%-100%) and propylene oxide, tissues were 
embedded in Epon (Fluka). Tissue in Epon-block was further trimmed with an 
ultramicrotome (EM UC7, Leica). 1 µm semithin sections were cut and stained with 1% 
toluidine blue for light microscopy. For electron microscopy, 70 nm ultrathin sections 
were cut and stained with 2% uranyl acetate (Plano GMBH) and reynolds solution 
containing 3.52% sodium citrate (Electron Microscopy Sciences), 2.66% lead nitrate 
(Electron Microscopy Sciences) and 160 mM Sodium hydroxide. Images were acquired 
with a transmission electron microscope (CM10, Phillips) equipped with Orius 
SC200W camera. 
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3.5 Cell counting and axon morphometry 
3.5.1 Cell counting 
At least 3 mice per genotype at each time point were used for quantification. 
Quantification was performed on forebrain coronal sections, cerebellum sagittal 
sections at comparable levels, and spinal cord at lumbar levels. Low-magnification 
photographs of non-overlapping fields covering the lateral part of the corpus callosum, 
the most medial part of the internal capsule of one hemisphere and ventral grey matter 
of the spinal cord were taken and used for quantification. For the quantitative analysis 
of dark cells in the ventral white matter of spinal cords, at least 3 semithin micrographs 
of each mouse were used. One section per mouse was employed. APC+, Olig2+, mt-
YFP+, or dark cells were counted manually. The cell size of APC+ cells was quantified 
on images acquired using the same exposure time by the measure function of 
Axiovision software (Zeiss). 
3.5.2 g ratio and myelinated axon counting 
The number of myelinated axons in the lumbar part of the spinal cord was quantified 
from micrographs of semithin sections using ImageJ particle analyzer with the setting of 
size 50-infinity and circularity 0.3-1.0. The g ratio was determined by measuring the 
diameter of inner axon and total outer on electron micrographs using Photoshop. 3 mice 
per genotype were analysed. 
3.6 Oligodendrocytes preparation 
Brains from P5 pups were removed and manually dissociated with the Neuronal Tissue 
Dissociation Kit (130-092-628, Miltenyi Biotec). Briefly, the weight of brain was 
determined in ice-cold HBSS without Ca2+ and Mg2+ (55021C, Sigma). Afterwards, the 
brain was cut into small pieces and mechanically dissociated in pre-warmed enzyme 
mix (as specified in the manufacturer’s instruction) at 37°C. The cell suspension was 
applied to a 40 µm cell strainer (BD Falcon) and washed with HBSS with Ca2+ and 
Mg2+ (55037C, Sigma). After centrifugation, cells pellets were resuspended in 0.5% 
BSA in PBS. To purify oligodendrocytes, the cell suspension was further incubated 
with anti-O4 magnetic beads (130-094-543, Miltenyi Biotec) for 15 min at 4°C. Next, 
the cell suspension was washed and applied onto MACS column (130-042-201, 
Miltenyi Biotec), which was placed in a magnetic field of the MACS separator (130-
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042-302, Miltenyi Biotec). The magnetic labelled O4+ cells were retained within the 
columns, while flow-through was collected. MACS column was removed from the 
magnetic MACS separator, after adding 1 ml buffer containing 0.5% BSA in PBS, O4+ 
cells were flushed out by pushing the plunger into the column. After centrifugation, cell 
pellet was stored at -80°C till use. 
3.7 Biochemistry 
3.7.1 Isolation of crude mitochondria  
Mitochondrial preparation was performed as previously described (Wieckowski et al., 
2009). Tissues were homogenized in ice-cold isolation buffer (225 mM Mannitol, 75 
mM Sucrose, 30 mM Tris-HCl, 1mM EGTA, 0.5% BSA) using Potter S (Sartorius). 
The homogenate was centrifuged at 800 g for 5 min at 4°C, and the supernatant was 
collected and centrifuged at 10,000 g for 10 min at 4°C. The pellet was resuspended in 
mitochondrial resuspending buffer (225 mM Mannitol, 5 mM HEPES, 0.5 mM EGTA). 
After centrifugation at 10,000 g for 10 min at 4°C, the pellet was finally resuspended in 
mitochondrial resuspending buffer, and stored at -80°C till use. 
3.7.2 Myelin isolation 
Sucrose gradient centrifugation was used to purify myelin from mouse brain (Norton 
and Poduslo, 1973; Uschkureit et al., 2000). Briefly, half a brain was homogenized in 
10 ml 0.32 M sucrose with Potter S homogenizer (Sartorius). The homogenate was 
layered over 20 ml of 0.85 M sucrose, and centrifuged at 20,000 g for 30 min at 4°C. 
The interphase of crude myelin was collected with a pipette, and resuspended in 30 ml 
Millipore water. Following centrifugation at 20,000 g for 15 min at 4°C, the crude 
myelin pellets were resuspended again in 30 ml Millipore water and centrifuged at 
12,000 g for 10 min at 4°C. The myelin pellet was washed in water again, and was 
stored at -80°C till use. 
3.7.3 Protein extraction 
Mouse tissue was homogenized in RIPA buffer containing 50 mM Tris-HCl pH7.4, 150 
mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, and 
fresh protease cocktail inhibitor (P2714, Sigma) on ice. The homogenate was 
centrifuged at 20 000 g for 30 min at 4°C. The supernatant was harvested, and protein 
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concentration was determined with Bio-Rad protein assay based on Bradford method 
(500-0006, Bio-Rad). Protein extraction from cells was similarly performed. Briefly, 
cells were lysed in RIPA on ice for 30 min, and the protein concentration was measured 
after high-speed centrifugation. The lysates from mouse tissues or cells were diluted 
into equal concentration, then were mixed with SDS sample loading buffer with a final 
concentration of 50 mM Tris-Cl pH 6.8, 2 % SDS, 10 % glycerol, 0.004 % 
bromophenol blue and 1 % of β-mercaptoethanol. After boiling 5 min on heating block 
(95oC), samples were subjected to immunoblot, or stored as aliquots at -80oC till use. 
3.7.4 Western blot 
Proteins were separated by 10% or 12% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) at constant 10-30 mA till the ladder was resolved ideally.  
Next, proteins were transferred onto 0.45 µm PVDF membrane (GE Healthcare) in a 
buffer containing 25 mM Tris, 192 mM glycine and 20% methanol. The blotting was 
conducted at constant 300 mA for 90 min at 4oC.  
Afterwards, the membrane was stained with in Ponceau solution (0.1% Ponceau S in 5% 
acetic acid) to visualize protein bands. The membrane was blocked in 5% milk or in 1 % 
western blot reagent (11921673001, Roche) in 0.1 % Tween 20 in TBS (TBST) and 
incubated with primary antibodies (Table 3.4) at 4oC overnight. After washing in TBST, 
the membrane was incubated with the secondary antibodies (Table 3.5), followed by 
washing in TBST. The membrane was then incubated with enhanced chemiluminescent 
(ECL) detection reagents (RPN2106, GE Healthcare) or ECL prime (RPN2232, GE 
Healthcare), exposed to X-ray films (4741019236, FUJIFILM), and developed in dark. 
Table 3.4 Primary antibodies for western blot 
Antibody Company or source Dilution 
AFG3L1 Home-made, Rugarli lab (Koppen 
et al., 2007) 
1:1000 
AFG3L2 Home-made, Rugarli lab (Koppen 
et al., 2007) 
1:1000 
AFG3L2 Home-made, Langer lab 
(Koppen et al., 2007) 
1:12500 
AMPK #2532, Cell signaling 1:1000 
Phospho-AMPK (Thr172) #2535, Cell signaling 1:1000 
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ATP5 a #ab14748, Abcam  1:1000 
CDK 5 #ab63550, Abcam 1:1000 
CNP #5922, Sigma 1:500 
CNX #ADI-SPA-860, Enzo 1:4000 
DRP1 (DLP1) #611112, BD Biosciences 1:1000 
Phospho-DRP1 (Ser616) #3455, Cell signaling 1:1000 
ERK1/2 #9102, Cell signaling 1:1000 
Phospho-ERK1/2 #4370, Cell signaling 1:1000 
GAPDH #MAB374, Chemicon 1:2000 
GFAP #Z0334, Dako 1:2000 
GSK3 β #9315, Cell signaling 1:1000 
Phospho-GSK3 α/β (Ser21/9) #9331, Cell signaling 1:1000 
JNK #9252, Cell signaling 1:1000 
Phospho-JNK #9255, Cell signaling 1:1000 
Phospho-MARK #4836, Cell signaling 1:1000 
MBP #SMI-94R, Covance 1:2000 
NDUFA9 #459100, Molecular Probes 1:1000 
OPA1 #612606, BD Biosciences 1:1000 
P35/25 #2680, Cell signaling 1:1000 
P38 #8690, Cell signaling 1:1000 
Paraplegin Home-made, Rugarli lab 
(Ferreirinha et al., 2004) 
1:500 
PHB #MS-261-P1, Thermo Scientific 1:1000 
PKA C-α #4782, Cell signaling 1:1000 
Phosphor-PKA C (Thr197) #4781, Cell signaling 1:1000 
SDHA #A-11142, Molecular probes 1:4000 
SOD2 (Mn-SOD) 06-984, Upstate 1:1000 
Tau (Tau-1) #MAB3420, Chemicon 1:1000 
Phospho-Tau (S202/T205) #MN1050, Pierce 1:1000 
Phospho-Tau (T181) #701530, Pierce 1:2000 
Phospho-Tau (S199) #710124, Pierce 1:2000 
Phospho-Tau (S396) #710298, Pierce 1:2000 
Tom20 #sc-11415, Santa Cruz 1:1000 
β-III tubulin #T8660, Sigma 1:1000 
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Table 3.5 Secondary antibodies for western blot 
Antibody Company  Dilution 
Anti-mouse lgG #A9044, Sigma 1:10000-1:30000 
Anti-rabbit lgG #A0545, Sigma 1:5000-1:10000 
 
3.7.5 Oxyblot 
To detect oxidative proteins modified by oxygen free radicals and other reactive species, 
Oxyblot protein oxidation detection kit (S7150, Millipore) was applied. Briefly, 10-20 
µg proteins per sample were denatured in SDS and then treated with DNPH solution for 
15 min at room temperature. For the negative control, derivatization-control solution 
was employed instead of DNPH solution. The reaction was stopped by adding 
neutralization solution. Afterwards, standard western blot was conducted with the 
primary antibody  (dilution 1:150) and secondary antibody (dilution 1:300) provided in 
the Oxyblot kit.  
If not stated specifically, all chemicals used in this study were purchased from Sigma. 
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3.8 Statistical analysis  
3.8.1 Chi-square test 
χ2 was calculated with the formula below, and cumulative probability was calculated 
with an online calculator (http://www.danielsoper.com/statcalc/calculator.aspx?id=11). 
 
3.8.2 Unpaired Student’s t test  
Unless stated otherwise, two-tailed unpaired t test was performed using GraphPad Prism 
6 software, presenting the data as mean ± standard error of the mean (S.E.M.).  
3.8.3 Two-way ANOVA test  
Two-way ANOVA test was performed using GraphPad Prism 6 software, presenting the 
data as mean ± standard error of the mean (S.E.M.). 
All statistical significance is defined as *p < 0.05, **p< 0.01, ***p < 0.001 and ****p < 
0.0001. 
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4 Results 
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4.1 Afg3l2 full-body knockout mice show severe developmental 
phenotype 
It has been previously shown that mouse models carrying null or missense homozygous 
mutations of Afg3l2 display axonal development defects and die generally at P16 
(Maltecca et al., 2008), however the pathogenesis was not completely understood. To 
gain new insights into the pathogenic mechanism, I further analyzed the Afg3l2 null 
mutant mice, which was generated in FVB strain by integration of ecotropic murine 
leukemia virus insertion 66 (EMV66) within intron 14 of the Afg3l2 gene (Maltecca et 
al., 2008). Western blot analysis confirmed that neither full-length nor truncated form of 
AFG3L2 was present in Afg3l2EMV66/EMV66 mice (Maltecca et al., 2008). Therefore, 
Afg3l2EMV66/EMV66 mice are bona-fide knockouts, hereafter referred to as L2 KO. 
4.1.1 Phenotypic complexity of L2 KO mice 
When Afg3l2+/EMV66 line was hosted in our animal facility, we were not able to obtain 
L2 KO mice in a pure FVB background. To increase the birth rate of L2 KO mice, we 
decided to set up the breedings in a mixed FVB-C57BL/6 genetic background (Figure 
3.1 in material and methods). Nonetheless, the percentage of L2 KO mice was 8.8% at 
P12 (Figure 4.1 A), and the mutants died before 3 weeks of age. We analyzed the mice 
at P12, in the middle-late stage of disease progression. As expected, L2 KO mice 
showed a severe muscle weakness and body weight reduction at P12 (Figure 4.1 B, C). 
Consistent with myelination defects in the spinal cord of AFG3L2 mutants (Maltecca et 
al., 2008), both immunofluorescence staining and western blot analysis to detect 
specific myelin proteins showed a reduction of MBP (Kondadi et al., 2014) and CNP in 
the brain (Figure 4.1 D, E), suggesting a global myelination defect throughout the CNS 
of L2 KO mice. 
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Figure 4.1 Characterization of Afg3l2 full-body knockout mice. 
(A) Distribution of different genotypes of animals at P12. Chi-square test, χ2 = 27.91, probability 8.7 x 
10-7. Observed Afg3l2+/+ (L2 WT) n = 58, Afg3l2+/EMV66 (L2 HET) n = 126, Afg3l2EMV66/EMV66  (L2 KO) n = 
18. (B) Representative picture of one L2 KO mouse compared to a wild type littermate at P12. (C) Body 
weight reduction of L2 KO at P12. L2 WT n = 58, L2 HET n = 126, L2 KO n = 18. (D) 
Immunofluorescence staining of myelin protein MBP on coronal brain sections reveals myelin defect in 
the L2 KO mice. n = 3 per genotype. Scale bar, 50 µm. (E) Western blot shows myelin protein CNP 
reduction in the brain lysates of L2 KO mice at P12.  
  
B
od
y 
w
ei
gh
t (
g)
A B
C D
0
4
8
12
 
****
****
0
10
20
30
40
50
60
Pe
rc
en
ta
ge Expected
Observed
L2 WT
L2 WT
L2 WT
L2 HET L2 KO
L2 KO
L2 KO
L2 WT
L2 WT
L2 HET L2 KO
L2 KOE
CNP
MBP
CNX 90 kDa
46 kDa
48 kDa
  49 
4.1.2 Loss of Afg3l2 unbalances mitochondrial fission and fusion 
Since mitochondria are dynamic organelles undergoing fusion and fission constantly, 
perturbation of the balance between fusion and fission could change the fate of 
mitochondria and consequently affects neuronal survival (Chen and Chan, 2009; Itoh et 
al., 2013). Increased fission or fusion defects could result in mitochondrial 
fragmentation, while the opposite leads to mitochondrial elongation. Previous studies 
have shown that knockdown of Afg3l2 leads to mitochondrial fragmentation via 
increased OPA1 processing (Ehses et al., 2009). Consistently, in Afg3l2 full-body 
knockout mice, mitochondria were fragmented and swollen (Figure. 4.2 A). The 
fragmentation may be explained by the enhanced cleavage of OPA1 long isoforms that 
are required for mitochondrial fusion (Figure. 4.2 B), whereas it is unknown if 
mitochondrial fission protein DRP1 is also affected. To assess this possibility, I checked 
the levels of the mitochondrial fission protein DRP1 (Smirnova et al., 2001) in the brain 
of mice at P12. Notably, the total DRP1 level was significantly decreased in the L2 KO 
mice (Figure. 4.2 B). DRP1 promotes mitochondrial fission when Ser 616 is 
phosphorylated (DRP1 pS616) (Taguchi et al., 2007). Interestingly, DRP1 pS616 was 
also reduced in the L2 KO mice (Figure. 4.2 B). Cytosolic DRP1 is recruited to 
mitochondria to mediate mitochondrial division (De Vos et al., 2005; Korobova et al., 
2013), thus I also examined DRP1 level in isolated mitochondrial fraction. The level of 
DRP1 in mitochondrial fraction was significantly diminished in the absence of AFG3L2 
(Figure. 4.2 C), suggesting less mitochondrial fission events occur in L2 KO mice. 
Taken together, our data suggest that AFG3L2 deficiency leading to mitochondrial 
fragmentation and is caused by OPA1 regulated fusion impairment rather than increased 
fission.  
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Figure 4.2 Disturbed mitochondrial dynamics in L2 KO mice.  
(A) Ultrastructural analysis of mitochondrial morphology in neurons of the brain. M: mitochondria; N: 
nucleus. Scale bar, 1 µm. (B) Immunoblot analysis of mitochondrial fusion/fission proteins OPA1 and 
DRP1 in total brain lysates from P12 pups. Quantification of the intensity of DRP1 and active form of 
DRP1 phosphorylated at Ser 616 (DRP1 pS616) normalized to loading control GAPDH is shown on the 
right. (C) Immunoblot analysis of DRP1 in crude mitochondrial fraction from the brain of P12 pups. 
Quantification of the intensity of DRP1 normalized to loading control SDHA is shown on the right. n = 3 
per genotype for all experiments. 
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4.1.3 Lack of Afg3l2 triggers tauopathy 
Utrastructural analysis of mitochondrial morphology in the brain of L2 KO mice 
unexpectedly showed that microtubules were disorganized and fragmented in neurons 
(Figure 4.3 A) (Kondadi et al., 2014). Tau is a well-known microtubule associated 
protein, and tau hyperphosphorylation has been implicated in Alzheimer's diseases (AD) 
(Alonso et al., 1996; Butner and Kirschner, 1991; Cleveland et al., 1977; Drubin et al., 
1986; Mandelkow and Mandelkow, 1998; Stoothoff and Johnson, 2005). 
Hyperphosphorylated tau detaches from microtubules, forms neurofibrillary tangles and 
results in microtubular disintegration and eventually neuronal death (Stoothoff and 
Johnson, 2005). To test if tauopathy is linked to Afg3l2 deficiency, we analysed tau 
levels in the L2 KO mice at P12. Immunoblot showed a dramatic increase of 
phosphorylated tau at various sites including T181, S199, S202, T205, S396, 
hyperphosphorylation of which has been involved in the pathogenesis of Alzheimer's 
disease (Martin et al., 2013b), whereas total tau level was not changed in the brain of L2 
KO mice (Figure 4.3 B) (Kondadi et al., 2014). Importantly, a significant increase of 
insoluble phosphorylated tau was present in the brain lysate pellets of L2 KO mice 
(Figure 4.3 C). These data indicate that Afg3l2 deficiency triggers tau 
hyperphosphorylation and tau pathology.  
4.1.4 Investigation of possible kinases involved in tau hyperphosphorylation 
Protein kinases regulate tau phosphorylation, and abnormal kinase activation has been 
implicated in tau hyperphosphorylation observed in the brain of AD patients (Martin et 
al., 2013b). To investigate potential kinases leading to tau hyperphosphorylation in the 
brain of the L2 KO mice, I tested steady state levels of multiple tau kinases, such as 
PKA, CDK5, JNK, ERK1/2, which have been shown to cause tau hyperphosphorylation 
in AD (Martin et al., 2013b). However, none of the kinases examined was dysregulated 
either in the total brain lysates or mitochondrial lysates in the L2 KO mice (Figure 4.4 A, 
B).  
Oxidative stress has been identified as one of the earliest events in the pathogenesis of 
AD (Lovell and Markesbery, 2007; Onyango and Khan, 2006; Zafrilla et al., 2006; Zhu 
et al., 2004). Moreover, haploinsufficiency of Afg3l2 mouse model showed increased 
reactive oxygen species (ROS) production (Maltecca et al., 2009). We therefore 
explored possible oxidative damage in our L2 KO mice. Unexpectedly, oxidative stress 
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markers SOD2, and carbonyl groups in oxidative proteins were comparable to the 
control (Figure 4.4 B, C) (Kondadi et al., 2014).  
 
Figure 4.3 Microtubule fragmentation and tau hyperphosphorylation in the L2 KO mice. 
(A) Electron micrographs of cortical neuronal processes show microtubule disruption in the L2 KO mice. 
M: mitochondrion; asterisks: microtubules. Scale bar, 0.5 µm. n = 3 per genotype. (B) Immunoblot 
analysis of tau and phospho-tau levels in the total brain lysates. While total tau levels were not changed, 
the levels of phosphorylated tau at various sites were increased. (C) Immunoblot analysis of insoluble 
phospho-tau at sites S202 and T205 in the brain.  
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Figure 4.4 L2 KO mice show normal kinase activity and no overt signs of oxidative damage 
(A, B) Total lysates (A) and mitochondrial fraction (B) from the brain of P12 pups were subjected to 
western blot and indicated antibodies were probed. No overt kinase upregulation was observed in this 
mouse model. (C) Oxy-blot showed similar levels of protein carbonyl groups in brain total lysates and 
mitochondrial fraction of pups at P12.  
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4.2 Afg3l2 forebrain-neuron specific knockout mice show early-onset 
neurodegeneration 
Since L2 KO mice show developmental phenotype and tau phosphorylation is increased 
during neonatal development, tau hyperphosphorylation observed in the L2 KO mice 
might be explained by general developmental dysregulation or a possible link between 
AFG3L2 and tau phosphorylation levels. To circumvent effects of Afg3l2 deletion 
during embryogenesis and early development, we generated a forebrain-neuron specific 
conditional knockout (AFG3L2NKO) mice by crossing Afg3l2flox/flox mice to mice 
constitutively expressing the Cre recombinase postnatally under control of the CaMKIIα 
promoter, which is active specifically in the forebrain starting at P20 (Minichiello et al., 
1999).  
4.2.1 Signs of neurodegeneration in AFG3L2NKO mice 
AFG3L2NKO mice developed a severe progressive phenotype starting at 8 weeks, and 
generally died at 12 weeks of age (observations by Anne Korwitz). At 8 weeks of age 
and later on, AFG3L2NKO mice showed lordokyphosis and abnormal behaviour, such as 
hind-limb clasping phenotype, and weight reduction (Figure 4.5 A, B). As expected, 
deletion of AFG3L2 was observed in the cortex and in the hippocampus, but not in the 
cerebellum (Figure 4.5 C) (Kondadi et al., 2014). We therefore analyzed AFG3L2NKO 
mice and the littermates at 8-10 weeks of age and focused on the cortex and the 
hippocampus. As early as 8 weeks, Nissl staining revealed massive neuronal loss in 
both cortex and hippocampus in the AFG3L2NKO mice (Figure 4.5 D) (Kondadi et al., 
2014). Thus, loss of AFG3L2 postnatally in neurons causes early onset 
neurodegeneration and subsequent premature death. 
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Figure 4.5 Deletion of Afg3l2 in forebrain-neurons causes neurodegeneration.  
(A) All AFG3L2NKO (L2NKO) mice showed limb-clasping phenotype, which is a sign of 
neurodegeneration. (B) The body weight was reduced in 8-10 week-old L2NKO mice. Females and males 
were pooled. CTRL: n = 10; L2NKO n= 9. (C) Immunoblot showed efficient AFG3L2 depletion in the 
hippocampus and cerebral cortex, while its expression level in the cerebellum was normal. (D) Brain 
coronal sections from 8-week old mice were stained with Nissl solution. Pronounced neuronal 
degeneration was shown in the cerebral cortex and hippocampus. n = 3 mice per group. Scale bar, 50 µm 
(cortex), 200 µm (hippocampus). 
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4.2.2 Mitochondrial morphology aberration in AFG3L2NKO mice 
Ablation of the AFG3L2 in Purkinje cells in the cerebellum leads to mitochondrial 
fragmentation and altered distribution in the dendritic tree (Almajan et al., 2012), we 
therefore investigated the mitochondrial morphology upon postnatal deletion of the 
AFG3L2 in forebrain neurons. In line with the observations in Afg3l2 conditional 
Purkinje cell-specific KO (Almajan et al., 2012) and constitutive full-body KO mice 
(Figure 4.2 A), immunostaining of COX1 showed that mitochondria were fragmented 
and swollen in cortical neurons of AFG3L2NKO mice (Figure 4.6 A). Ultrastructural 
studies further revealed that these abnormal mitochondria were dramatically devoid of 
cristae (Figure 4.6 B). Hence, we conclude that postnatal deletion of Afg3l2 is sufficient 
to cause mitochondrial morphological alternations in neurons.  
4.2.3 Tau hyperphosphorylation in AFG3L2NKO mice 
To exclude that tau hyperphosphorylation in the L2 KO mice is because of 
developmental defects, we next examined tau levels in the adult AFG3L2NKO mice. As 
expected, similar to what was observed in the L2 KO mice (Figure 4.3 B), western blot 
revealed more phosphorylation of tau in the cortex and in the hippocampus of 
AFG3L2NKO mice (Figure 4.7 A) (Kondadi et al., 2014), indicating that a causal link 
between AFG3L2 deficiency and tauopathies. 
In comparison to L2 KO mice that die before 3 weeks, AFG3L2NKO is an adult mouse 
model, which is more representative of the progressive phenotype of the human diseases. 
We then set out to investigate whether kinases are activated in this model and could 
account for tau hyperphosphorylation. Remarkably, the activated form of kinase 
ERK1/2 and PKA at corresponding phosphorylation sites were enhanced in the 
AFG3L2NKO mice (Figure 4.7 B) (Kondadi et al., 2014). In contrast, the activity of other 
kinases was unchanged, with the exception of increased levels of the inactivate form of 
GSK3 kinase phosphorylated at Ser9/21, indicating that GSK3 kinase was inhibited in 
our mouse model. To determine whether oxidative damage evoked the observed kinases 
activation, I checked the SOD2 levels and protein carbonyl groups. However, in 
comparison to the controls, AFG3L2NKO showed identical levels of carbonylated 
proteins and SOD2 (Figure 4.7 C) (Kondadi et al., 2014). 
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To address whether mitochondrial dysfunction per se could cause tau 
hyperphosphorylation, I analysed brains from Surf1, Sco2 and NDUFS4 mouse models 
with mitochondrial respiration defects. Surfeit locus protein 1 (Surf1) is a putative 
assembly factor of respiratory complex IV, which mutations have been found in a 
severe neurological disorder Leigh Syndrome characterized by bilaterally symmetrical 
necrotic lesions in the brain (Zhu et al., 1998). Surf1 mutation or deletion causes COX 
activity reduction (Viscomi et al., 2011; Zhu et al., 1998). Deficiency of COX assembly 
protein isoform 2 (Sco2), a copper chaperone of the COX subunit II (COX2), results in 
decreased COX activity and leads to fatal infantile cardioencephalomyopathy 
(Dickinson et al., 2000; Papadopoulou et al., 1999; Yang et al., 2010). Ndufs4 is a 
complex I subunit, which mutations also has been implicated in Leigh Syndrome (Benit 
et al., 2003). Ndufs4 deficiency impairs complex I assembly and decreases its activity 
(Ingraham et al., 2009; Papa, 2002). Interestingly, negligible phosphorylated tau levels 
were detected in these mutated mice compared to the controls (Figure 4.7 D). Hence, we 
conclude that tauopathy is specially associated to AFG3L2 deficiency, and is not a 
feature for all mitochondrial dysfunction. 
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Figure 4.6 Loss of Afg3l2 in forebrain neurons postnatally leads to mitochondrial disruption. 
(A) Immunofluorescence staining of COX1 on brain coronal sections indicates mitochondrial 
morphological aberration in the cortical neurons of L2NKO mice at 8 weeks of age. n = 2 per group. Scale 
bar, 10 µm. (B) Electron micrographs of cortical neurons show swollen mitochondria with few cristae in 
the brain of L2NKO mice at 8 weeks of age. M: mitochondria; N, nucleus. n = 3 per group. Scale bar, 1 
µm. 
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Figure 4.7 Tau hyperphosphorylation and kinases investigation in the adult AFG3L2NKO mice 
(A) Tau was hyperphosphorylated at various sites in the hippocampus and cerebral cortex of AFG3L2NKO 
(L2NKO) mice. (B) The ERK1/2 and PKA kinases were activated in the hippocampus and the cortex of 
Afg3l2NKO mice. GSK3 kinase was inhibited at the phosphorylation sites S9/21, whereas other kinases 
appeared unchanged. (C) Oxy-blot and western blot analyses revealed neither any evident oxidative 
damage in the hippocampus and cerebral cortex, nor an overexpression of SOD2 was detected. (D) 
Mitochondrial respiration deficient mouse models showed negligible tau phosphorylation and comparable 
OPA1 isoforms in the brain. Brains of Surf1-/- (Surf1 KO) mice, Sco2 knockout/knockin mice (Sco2 
KOKI) harboring a Sco2 knockout allele and a Sco2 knockin allele expressing a mutation of E129K, and 
Ndufs4-/- (Ndufs4 KO) and control mice were kindly provided by Massimo Zeviani. 
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4.3 Afg3l2 oligodendrocytes-specific knockouts display late-onset 
myelin abnormalities 
Previous results have clearly indicated that AFG3L2 is essential for the survival of 
neurons, yet its role in glial cells is unknown. Oligodendrocytes and Schwann cells are 
myelinating glial cells in the central nervous system (CNS) and peripheral nervous 
system (PNS), respectively. To investigate the role of AFG3L2 in myelinating cells, I 
investigated the expression levels of the m-AAA protease subunits in oligodendrocytes 
and explored the effects of deleting Afg3l2 specifically in adult oligodendrocytes. 
4.3.1 AFG3L2 is abundantly expressed in oligodendrocytes 
AFG3L2 is highly expressed in the murine brain (Koppen et al., 2007), but its 
expression in myelin-forming cells remains undetermined. To address this question, I 
isolated immature oligodendrocytes from P5 pups using magnetic anti-O4 microbeads. 
Western blotting showed that the isolation was successful as indicated in the elution 
fraction, in which the oligodendrocytes marker MBP was highly enriched whereas the 
neuronal marker β-III tubulin was present in negligible amount (Figure 4.8). Notably, 
AFG3L2 was abundantly expressed in purified oligodendrocytes in comparison to other 
m-AAA protease subunits AFG3L1 and paraplegin (Figure 4.8).  
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Figure 4.8 The expression levels of m-AAA protease subunits in oligodendrocytes. 
O4+ immature oligodendrocytes were isolated from the brain of P5 pups by using anti-O4 magnetic 
beads. Immunoblot for the oligodendrocyte marker MBP and the neuronal marker β-III tubulin showed 
successful isolation in the eluate compared to the input and the flow-through. Succinate dehydrogenase A 
(SDHA) and calnexin (CNX) were used as loading controls. n = 2 experiments on pups at P5, and similar 
results were obtained from one experiment on pups at P4.  
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4.3.2 The PLP1 promoter is efficiently and specifically expressed in 
oligodendrocytes in the adult mice 
The PLP1 promoter drives the expression of the major component of myelin in CNS-
the proteolipid protein 1 (PLP1), and its splice variant DM-20, which is largely 
expressed during early development in both neuronal and oligodendrocyte precursors 
(Ikenaka et al., 1992; Timsit et al., 1995). The PLP1 promoter is therefore expressed in 
multi-lineage cells during embryonic and early postnatal stages (Delaunay et al., 2008; 
Guo et al., 2009; Michalski et al., 2011). To further evaluate the temporal and spatial 
expression of Cre under the PLP1 promoter, I crossed tamoxifen inducible PLP1-
CreERT transgenic mice (Doerflinger et al., 2003) with mice expressing a 
mitochondrially targeted YFP (mt-YFP) activated upon Cre recombination 
(ROSA26+/SmY) (Sterky et al., 2011). Tamoxifen was administered either to a pregnant 
female mouse at embryonic day 15.5 (E15.5) for one day or to adult mice at 4 weeks of 
age for 5 consecutive days. Pups from the female mouse that received tamoxifen at 
E15.5 were analysed at P15. In the CNS, the mt-YFP signal was mainly localized in 
cells that were stained with the mature oligodendrocytes marker APC in the brain stem, 
and also partially in cells showing the morphology of immature oligodendrocytes in the 
ventral brain (Figure 4.9). Moreover, the mt-YFP was expressed in molecular layers of 
the cerebellum likely in Bergmann glial cells, but was not observed in the corpus 
callosum or in the cortex (Figure 4.9). In contrast, in mice that had received tamoxifen 
at 4 weeks and were analysed at 10 weeks of age (Figure 4.10 A), the mt-YFP+ signal 
was selectively present in mature oligodendrocytes, recognized by their expression of 
the marker APC+ throughout the CNS (Figure 4.10 B). Quantification of the 
colocalization of the mt-YFP+ and the APC+ cells showed that Cre excision occurred in 
approximately 50% of mature oligodendrocytes in different regions (Figure 4.10 C). In 
addition, the specificity of the PLP1 promoter was approximately 97% in the CNS, 
which was obtained by calculating the number of mt-YFP+ that also APC+ cells dividing 
the total number of mt-YFP+ cells. In the PNS, dispersed mito-YFP signal was present 
in Schwann cells (Figure 4.10 D). Thus, despite that the Cre expression is not restricted 
to myelinating cells at the embryonic stage, PLP1 promoter driven Cre expression is 
highly specific at a later postnatal stage. Based on this, all mice in the following 
experiments were injected with tamoxifen at 4 weeks of age for 5 consecutive days.  
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Figure 4.9 PLP1 promoter-driven Cre recombination is not restricted to oligodendrocytes lineage at 
early developmental stage. 
Tamoxifen was administered to a pregnant female mouse at ~E15.5 for one day, and the pups were 
analyzed at P15. Representative brain sections were stained with APC, a marker for mature 
oligodendrocytes (B, E, H, K) and mitochondria in recombined cells were visualized by endogenous YFP 
signal (A, D, G, J). Nuclei were counterstained with DAPI (C, F, I, L). Scale bar: 20 µm. n = 3 pups from 
one litter were analyzed. 
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Figure 4.10 PLP1 expression is restricted to myelinating cells in the adult. 
(A) Schematic representation of the timeline of tamoxifen injection and analysis. (B) Brain and spinal 
cord sections from PLP1-CreERT+/tg ROSA26+/SmY mice treated as described in (A) were stained with the 
mature oligodendrocyte marker APC. Mitochondria in targeted cells were visualized by endogenous YFP 
signal. Scale bar, 50 µm. (C) Quantitative analysis of recombination efficiency. n = 3 mice. CC: corpus 
callosum; CB: cerebellum; SC: spinal cord. (D). Dispersed YFP-labeled mitochondrial signal was 
observed in the sciatic nerve. S100, Schwann cell marker; SMI31, neurofilaments marker. n =3 mice. 
Scale bar, 10 µm. 
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4.3.3 Deletion of Afg3l2 induces mitochondrial abnormalities in oligodendrocytes 
Since loss of AFG3L2 in adult forebrain neurons (Figure 4.6) and cerebellar Purkinje 
cells leads to fragmented and swollen mitochondria (Almajan et al., 2012), we 
investigated the mitochondrial morphology in AFG3L2-deficient oligodendrocytes. To 
this end, we generated Afg3l2 myelinating cells-specific knockout mice (L2MC-KO) by 
crossing conditional Afg3l2 floxed mice (Almajan et al., 2012) to PLP1-CreERT mice 
(Doerflinger et al., 2003). To visualize the mitochondrial morphology when Afg3l2 is 
deleted, mice from this double line were mated with ROSA26+/SmY mice (Sterky et al., 
2011). Remarkably, mitochondria in the L2MC-KO mice were fragmented and swollen as 
early as at 8 weeks, and this alteration persisted at 56 weeks of age (Figure 4.11 A). 
Indeed, ultrastructural analysis of 56-week-old L2MC-KO mice further confirmed the 
presence of enlarged mitochondria with reduced cristae (Figure 4.11 B). To examine the 
functionality of these mitochondria, I performed immunostaining of COX1 that is a 
mitochondrially encoded subunit of the respiratory chain complex IV. Confocal 
microscopy validated that these mitochondria appeared fragmented and swollen in the 
L2MC-KO mice, but COX1 staining was retained in these abnormal mitochondria (Figure 
4.11 C). Notably, since the targeting presequence of YFP is from a mitochondrial 
matrix protein in ROSA26+/SmY (Sterky et al., 2011), the YFP should be homogenous 
expressed in the mitochondrial matrix under normal conditions. However, in the brain 
of L2MC-KO mice at the age of 56 weeks, the YFP signal was heterogeneous with clumps 
in the periphery and little intensity in the centre of mitochondria. Co-staining with 
COX1, which is supposed to localize to the mitochondrial inner membrane, was also 
clumped but more towards the centre of the mitochondria (Figure 4.11 C), indicating 
that mitochondrial cristae was remodelled in oligodendrocytes lacking of AFG3L2. The 
intensity of COX1 did not reduce, indicating that the mitochondrial translation was not 
impaired in oligodendrocytes. Together, these data indicate that in the absence of 
AFG3L2, mitochondrial morphological alteration is an early event and mitochondrial 
translation might not be affected in oligodendrocytes.  
4.3.4 Lack of AFG3L2 does not affect the survival of oligodendrocytes 
AFG3L2 deficiency in neurons leads to early neuronal death (Almajan et al., 2012; 
Kondadi et al., 2014), thus the next question was to address whether the survival of 
oligodendrocytes is affected upon loss of AFG3L2. Notably, the number of targeted 
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oligodendrocytes labeled with mt-YFP+ in the L2MC-KO mice was comparable to control 
mice at 56 weeks of age (Figure 4.12 A, B), indicating normal viability of 
oligodendrocytes lacking AFG3L2. Therefore, it was not surprising that the total 
number of APC+ mature oligodendrocytes was not statistically different (Figure 4.12 A, 
C). However, quantitative analysis showed that the number of mt-YFP+ cells that were 
not stained by the mature oligodendrocyte marker APC antibody was significantly 
increased (Figure 4.12 A, D), suggesting that these mt-YFP+ cells were not mature 
oligodendrocytes. Thereby, we conclude that deletion of AFG3L2 in adult 
oligodendrocytes does not cause oligodendrocyte death but possibly affects their 
maturation.  
4.3.5 Late-onset motor impairment and axonal dysmyelination in the L2MC-KO mice 
To explore whether axonal myelination and integrity are affect in the spinal cord of 
L2MC-KO mice at 56 weeks of age, and I analysed the semithin sections of the spinal cord, 
and did not observed evident axonal demyelination or degeneration (Figure 4.13 A). 
However, electron microscopy study revealed some pathological axons with adaxonal 
myelin detachment and vacuolization (Figure 4.13 B). I then analysed the aged 90-
week-old L2MC-KO mice. Despite that L2MC-KO mice displayed identical body weight 
compared to the control littermates (Figure 4.13 C) and no obvious phenotype in the 
cage for all the time of analyses, these mice showed significant reduction of latency 
time to fall in the rotarod test, suggesting motor impairment at 90 weeks of age (Figure 
4.13 D). I further analysed the semithin sections of the spinal cord in these mice, and 
found evident of axonal dysmyelination and degeneration in the corticospinal tracts 
(Figure 4.13 E, F). Thus, loss of AFG3L2 in oligodendrocytes in adult mouse causes 
age-dependent axonopathy in the spinal cord. 
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Figure 4.11 Disturbed mitochondrial dynamics in oligodendrocytes of L2MC-KOmice. 
(A) YFP+ mitochondria in targeted oligodendrocytes were visualized by anti-GFP immunostaining. 
Nuclei were counterstained with DAPI. At 8 weeks of age, L2wt/fl (PLP1-
CreERT+/tg/Afg3l2wt/fl/ROSA26+/SmY) littermates were compared to L2MC-KO (PLP1-
CreERT+/tg/Afg3l2fl/fl/ROSA26+/SmY). At 56 weeks of age, wild type mice (PLP1-
CreERT+/tg/Afg3l2wt/wt/ROSA26+/SmY) were compared to L2MC-KO (PLP1-
CreERT+/tg/Afg3l2fl/fl/ROSA26+/SmY) mice. Scale bar, 10 µm. (B) Electron micrographs of cortical 
oligodendrocytes show a swollen mitochondrion lack of cristae in the L2MC-KO mice. N, nuleaus; M, 
mitochondrion. Scale bar, 0.5 µm. (C) Deconvoluted single-plane confocal images showing that COX1 
staining was retained in swollen mt-YFP+ mitochondria in L2MC-KO mice. Scale bar, 1 µm. n = 3 or 4 mice 
per group for all experiments. 
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Figure 4.12 AFG3L2 is essential for oligodendrocyte maturation not for their survival.  
(A) Immunofluorescence double staining of GFP and APC in coronal brain sections from 56-week-old 
mice. n = 3 or 4 animals per group. GFP staining visualizes targeted mt-YFP+ cells, and mature 
oligodendrocytes were labeled by APC in the corpus callosum. Nuclei were counterstained with DAPI. 
CC: corpus callosum. Arrowhead indicates mt-YFP+ cells that are APC-, indicating that these cells are not 
mature oligodendrocytes. Scale bar, 50 µm. (B-D) Quantification of mt-YFP+ cells (B), APC+ cells (C), 
and mt-YFP+ cells that were not stained by APC (D) in the panel A. 
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Figure 4.13 Deletion of Afg3l2 in oligodendrocytes causes late-onset motor impairment and 
dysmyelination. 
(A) Representative semithin micrographs of the white matter in the lumbar spinal cord showed 
comparable myelination and axonal integrity in 56-week-old L2fl/fl and L2MC-KO mice (n= 3 per genotype). 
Scale bar, 20 µm. (B) Ultrastructural analysis of the lumbar spinal cord white matter in 56-week-old mice 
showing adaxonal vacuolization (star) and myelin detachment (arrowhead) in L2MC-KO mice. Scale bar, 
0.5 µm. (C) Body weight of 90-week-old L2fl/fl and L2MC-KO mice. (Females: L2fl/fl n = 6, L2MC-KO n = 3; 
males: L2fl/fl n = 3, L2MC-KO n = 4). (D) Latency time to fall from a rotarod apparatus of 90-week-old mice 
(n = 10 mice per genotype). 3 trials (T) per 3 consecutive days (D) were performed. Two-way ANOVA 
test, p < 0.0001. (E) Representative semithin micrographs of the spinal cord white matter in 90-week-old 
mice. Arrows indicate dark degenerating axons and asterisks show thickened myelin. Scale bar, 10 µm. 
(F) Quantification of abnormal axons (dark degeneration or dysmyelination) in ventral corticospinal tracts 
of the spinal cord. n = 3 per group.  
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4.4 Afg3l1 full-body knockout mice show no evident sign of 
neurodegeneration 
The murine genome has a third m-AAA protease subunit, AFG3L1, which is similar to 
AFG3L2, and is capable of forming both homo- and hetero-oligomeric complexes 
(Koppen et al., 2007). In the mouse, AFG3L1 is expressed at high level in the liver but 
at low level in the brain (Koppen et al., 2007; Sacco et al., 2010). The function of 
AFG3L1 in the mouse is not well known, but it has been proposed to play 
compensatory role when AFG3L2 is absent (Ehses et al., 2009; Maltecca et al., 2008). 
To test whether AFG3L1 compensates for the loss of AFG3L2 in myelinating cells, I 
analysed the Afg3l1 full-body knockout mice, which was generated by our group but 
has not been published.  
4.4.1 Normal growth curve of Afg3l1 KO mice 
Afg3l1 constitutive KO mice were produced by deletion of exons 2 and 3 (Figure 4.14 
A), and were born at expected Mendelian ratio (Figure 4.14 B). These mice were fertile, 
and did not show any overt behavioral abnormalities. Moreover, the body weight of 
Afg3l1 KO mice (referred to as L1-/-) was comparable to the wild type (referred to as 
L1+/+) littermates till 1 year of age (Figure 4.14 C). Thus, we concluded that Afg3l1 KO 
mice grow normally compared to the wild type mice. 
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Figure 4.14 Generation of Afg3l1 full-body knockout (L1-/-) mice.  
(A) Schematic illustration of the gene targeting strategy. (B) Observed versus expected genotype 
distribution of Afg3l1 animal at ~ 4 weeks of age. Chi-square test, χ2 = 0.13, probability 0.94.  Wild type 
(L1+/+)  mice n = 19, Afg3l1+/- (L1+/-) mice  n = 38, and L1-/- mice n = 17. (C) Growth curves of L1+/+ and 
L1-/- mice. n ≥ 4 L1+/+ females and males, n ≥ 3 L1-/- females and males at each age group.  
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4.4.2 Preserved axonal myelination and integrity in Afg3l1 KO mice 
I have shown that lack of AFG3L2 is sufficient to induce stress-activated OPA1 
processing in the brain (Figure 4.2). This finding prompted us to examine the OPA1 
levels in the brain of Afg3l1 KO mice. Since AFG3L1 is highly expressed in murine 
liver (Koppen et al., 2007), I also investigated OPA1 cleavage in the liver. Immunoblots 
showed no evident accumulation of OPA1 short isoforms in tissues of 50-week-old 
L1KO mice (Figure 4.15 A), indicating that the absence of AFG3L1 is not sufficient to 
trigger extensive OPA1 processing in vivo. Gallyas myelin staining of the brain sections 
showed similar myelin patterns between Afg3l1+/- (referred to as L1+/-) and Afg3l1-/- 
(referred to as L1-/-) mice at 50 weeks of age (Figure 4.15 B). At the same age, axonal 
myelination and integrity in the L1-/- mice were comparable to the control L1+/- mice 
(Figure 4.15 C). In summary, Afg3l1 KO mice do not show any behavioural or obvious 
pathological abnormality in the CNS at least until 1 year of age. 
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Figure 4.15 Characterization of L1-/- mice. 
(A) Crude mitochondria were isolated from brains and livers of 50-week-old L1+/- and L1-/- mice, and 
immunoblots showed no overt OPA1 cleavage in both tissues of L1-/- mice. (B) Representative images of 
Gallyas myelin staining of the brain showing comparable myelin pattern between 50-week-old L1+/- and 
L1-/- mice. Scale bar, 1 mm. (C) Semithin micrographs of the white matter of the lumbar spinal cord 
revealing similar axonal integrity and myelination in 50-week-old L1+/- and L1-/- mice. n = 3 mice per 
genotype. Scale bar, 20 µm. 
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4.5 Ablation of the m-AAA protease in myelinating cells causes axonal 
demyelination and hair greying 
To achieve complete deletion of the m-AAA protease in myelinating cells, PLP1-
CreERTwt/tg mice (Doerflinger et al., 2003) were crossed with Afg3l2flox/flox mice 
(Almajan et al., 2012) in an Afg3l1 null background. Mice with the genotype PLP1-
CreERTwt/tg/Afg3l2flox/flox/Afg3l1-/- were referred to as DKO, and the control littermates 
with the genotype PLP1-CreERTwt/wt/Afg3l2flox/flox/Afg3l1-/- were referred to as CTRL. 
All CTRL and DKO mice were injected with tamoxifen at 4 weeks of age as previously 
described. 
4.5.1 DKO mice showed progressive motor impairment and hair greying 
DKO mice gained less weight compared to CTRL mice starting at 8 weeks of age 
(Figure 4.16 A). Interestingly, the fat content was also significantly lowered in the DKO 
mice (Figure 4.16 B). To test the motor balance and coordination, we performed rotarod 
and beam-walking tests. At about 13 weeks of age, DKO mice showed significant 
motor deficits in both tests, and progressive motor impairment was observed in the 
beam-walking test (Figure 4.16 C, D). These mice were bred in cages wherein they 
were required to balance themselves to grasp the grid to access their food. Therefore, 
since the DKO mice display motor deficits, it is conceivable that they potentially had 
difficulties to reach the food and hence showed body weight reduction. To exclude this 
possibility, we decided to put food pellets directly in the cage instead of on the grid after 
weaning. Remarkably, the body weight reduction of DKO mice persisted (Figure 4.16 
E). Furthermore, DKO mice displayed a specific and progressive hair-greying pattern. 
Hair greying started at ventral forelimbs, later at ventral hindlimbs, then proceeded to 
dorsal and head (Figure 4.16 F). Thus, loss of the m-AAA protease in PLP expression 
cells causes progressive neurological phenotype and hair greying.  
4.5.2 Genetic tracing of targeted cells in the skin 
The premature hair greying phenotype prompted us to study melanocytes, melanin-
producing cells localized in the skin. Previous studies have shown that the PLP1 is 
expressed in melanocytes or Schwann cells precursors (SCP) that also give rise to 
melanocytes, when the Cre is activated during embryonic development (Adameyko et 
al., 2009; Leone et al., 2003). However, the expression pattern of the PLP in adult mice 
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is unknown. To address this question, we first performed fate-mapping experiments 
with the PLP1-CreERT/ROSA26+/SmY line. Mice with the genotype PLP1-
Crewt/tg/ROSA26+/tg were injected with tamoxifen for 5 consecutive days starting from 
P29 and were sacrificed at P36. The ventral skin close to the forelimbs and the dorsal 
skin close to the thorax were examined. We detected mt-YFP+ signal mostly in Schwann 
cells in the subcutaneous plexus and to a less extent in the deep cutaneous plexus. We 
also identified moderate mt-YFP+ signal in melanocyte stem cells in the bulge, in 
melanoblasts in the outer root sheath, and in pigmented bulbar melanocytes in the hair 
follicle (Figure 4.17 A, B). Notably, we observed more mt-YFP+ signal in the ventral 
forelimb skin than in the dorsal part (Figure 4.17 A, B), indicating that the targeting 
efficiency is higher in the ventral skin, which is reflected in ventral to dorsal hair-
greying progression in the DKO mice. 
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Figure 4.16 DKO mice show a progressive neurological phenotype and hair greying 
(A) Weight curves of CTRL and DKO mice (males: n ≥ 5 per genotype; females: n ≥ 6 per genotype). (B) 
The fat content of mice determined by the quantitative magnetic resonance analyser (represent percentage 
of fat mass to body weight) at 13 weeks (n = 5 per genotype) and at 28 weeks of age (n = 4 CTRL and 5 
DKO). (C) Latency time to fall from a rotarod apparatus of mice at 11-13 weeks old. 5 CTRL and 10 
DKO mice were tested for 3 trials (T) in 3 consecutive days (D). Two-way ANOVA test, p < 0.05. (D) 
Quantification of foot slips during the beam walking test of mice at 13 weeks (n = 5 per genotype) and at 
28 weeks of age (n = 5 CTRL and 7 DKO). (E) Weight curves of DKO mice and CTRL mice when food 
was directly added in the cage (males: n ≥ 6 per genotype; females: n ≥ 8 per genotype). (F) All DKO 
mice (n > 15) displayed progressive ventral limbs to dorsal hair greying. 
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Figure 4.17 Fate mapping in the skin using PLP1-CreERT+/tg ROSA26+/SmY mice 
(A, B) Single-plane confocal images of dorsal (A) and ventral (close to forelimbs) (B) skin sections from 
PLP1-CreERT+/tg ROSA26+/SmY mice. Mice were injected with tamoxifen at P29 for five consecutive days 
and the skin was collected at P36. Endogenous mt-YFP+ signal in the cryosections is shown in green. SP: 
subcutaneous plexus; SG: sebaceous glands; BG: bulge area; DCP: deep cutaneous plexus; MC: 
melanocytes; ORS: outer root sheath. Scale bar, 10 µm. n = 3 mice. 
Note: Julie Jacquemyn contributed to Figure 4.17 A and B.  
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4.5.3 Loss of melanocytes and melanoblasts in the skin of DKO mice  
To monitor the fate of targeted cells in the DKO mice by using the mt-YFP reporter line, 
a quadruple line PLP1-CreERT/Afg3l2flox/flox/Afg3l1-/-/ ROSA26 was generated. Given 
the extreme low chance to get the ideal genotype of control and DKO mice from the 
same litter, DKO mt-YFPTg mice (PLP1-CreERTwt/tg/Afg3l2flox/flox/Afg3l1-/-/ROSA26+/SmY) 
were compared to the WT mt-YFPTg mice (PLP1-CreERTwt/tg/ROSA26+/SmY) from the 
PLP1-CreERT/ROSA26 line. In 10-week-old DKO mt-YFPTg mice, we observed an 
evident decrease of mt-YFP signal in melanoblasts in the outer root sheath of hair 
follicle, and in the non-myelinating Schwann cells in the subcutaneous nerve plexus 
(Figure 4.18 A). At 28 weeks of age, despite a reduction of deposited fat in the dermis, 
the skin structure and hair cycle were preserved in DKO mice (Figure 4.18 B). 
Therefore, we surmised that the hair greying in the DKO mice is not caused by hair 
cycle disturbance, but is possibly due to melanocytes maintenance failure. As expected, 
in the anagen phase in the dorsal skin, melanocytes and melanoblasts identified by the 
marker c-KIT were dramatically reduced in 28-week-old DKO mice (Figure 4.18 C), 
and consistently, the number of pigmented hair follicles was also significantly 
diminished (79.7 ± 2.9% in the CTRL versus 28 ± 12.3% in the DKO mice, n = 3, p < 
0.05, Julie Jacquemyn performed the quantification). Thus, our data suggest that the 
phenotype of hair greying in the DKO mice is caused by loss of melanocytes and 
melanoblasts. 
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Figure 4.18 Melanoblasts and melanocytes reduction in DKO mice 
(A) Confocal micrographs of the dorsal skin of 10-week-old CTRL and DKO mice carrying the mt-YFP 
transgene show loss of mt-YFP signal in the subcutaneous plexus (SP) and the outer root sheath (ORS). 
Scale bar, 10 µm. (B) Hematoxylin and eosin staining of dorsal skin of CTRL and DKO mice at 28 
weeks. Double-head arrows indicate the fat layer. Scale bar, 200 µm. (C) Confocal fluorescent and bright 
field images of the dorsal skin of 28-week-old CTRL and DKO mice. Several images were stitched using 
the tile scan function and show a total area of 0,74 mm2. c-KIT positive cells and pigmented HFs were 
largely decreased in DKO mice. Nuclei were counterstained with DAPI. Scale bar, 100 µm. At least 3 
mice per group were used for all experiments. 
Note: Julie Jacquemyn contributed to Figure 4.18 A and C. 
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4.5.4 Peripheral neuropathy in the DKO mice 
Non-myelinating Schwann cell reduction in the nerve plexus in the skin of DKO mice 
prompted us to examine whether Schwann cells in the sciatic nerve were also affected. 
Consistent with the loss of mt-YFP+ Schwann cells in the subcutaneous nerve plexus 
(Figure 4.18 A), mt-YFP+ Schwann cells in the sciatic nerve were also prominently 
reduced in the 10-week-old DKO mice (Figure 4.19 A). In spite of this, from the 
semithin sections of sciatic nerves, we could not see obvious differences between DKO 
and CTRL at both 10 weeks and 28 weeks of age (Figure 4.19 B). Given the fact that 
PLP1 is not highly expressed in Schwann cells in the adult (Doerflinger et al., 2003), 
presumably we need a more refined technique to assess these limited amount of targeted 
Schwann cells, To this end, we conducted electron microscopy studies. Ultrastructural 
analysis showed pathological signs of unmyelinated C fibers (also known as Remark 
bundles) in the DKO mice (Figure 4.19 C). At 10 weeks of age, while non-myelinated 
axons were separated by the cytoplasm of Schwann cells in the CTRL, individual axons 
were intimately touching each other in the DKO mice (Figure 4.19 C). We also 
observed adaxonal myelin detachment in a few big calibre axons in the DKO mice 
(Figure 4.19 C). These signs of axonal degeneration were more pronounced at 28 weeks 
of age, where a few non-myelinated large-calibre axons were found (Figure 4.19 C). 
Taken together, we conclude that deletion of m-AAA protease in adult mice leads to 
Schwann cell loss and preferentially affects C fibers at early stage. 
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Figure 4.19 Neuropathy in the sciatic nerve of the DKO mice 
(A) Representative single-plane confocal images showing endogenous mt-YFP signal in the sciatic nerve 
of mice at 10 weeks of age (10 w). Reduction of the signal was prominent in DKO mice. Scale bar, 10 µm 
(B) Representative semithin micrographs of the sciatic nerves. No overt demyelination was observed in 
DKO mice. Scale bar, 20 µm. (C) Electron micrographs of the sciatic nerve at 10 weeks and at 28 weeks 
(28 w). While in CTRL mice normal Remak bundles were found, in DKO mice some unmyelinated axons 
were touching each other (arrow), and showed pathological alteration of adaxonal vacuolization 
(arrowhead). 28-week-old DKO mice also showed non-myelinated large caliber axon (empty star) and 
multivesicular disintegration of adaxonal myelin lamellae (filled star). Scale bar 1 µm. n=3 per genotype 
per age for all experiments. 
Note: Julie Jacquemyn contributed Figure 4.19 A.  
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4.5.5 Axonal demyelination and neuroinflammation in the DKO mice 
Despite the fact that large-caliber axons of motor neurons in the peripheral nerves were 
predominantly intact in the DKO mice, given the fact that the PLP1 promoter is more 
efficient in the CNS, we therefore sought to investigate the axonal myelination and 
integrity in the CNS. Overt signs of axonal demyelination were observed in the white 
matter of the forebrain and the cerebellum in the 28-week DKO mice (Figure 4.20 A). 
Similarly, at this age, axonal demyelination was evident in the spinal cord of DKO mice 
characterized by a decrease of myelinated fibers and an increase of the g ratio (the ratio 
of the inner axon diameter to the fiber diameter) (Figure 4.20 B-E). Moreover, the 
number of abnormal dark cells was significantly enhanced in the DKO mice (Figure 
4.20 B, C). Ultrastructural analysis further confirmed the progressive axonal 
demyelination and dysmyelination in the DKO mice, and secondary axonal 
degeneration was also observed (Figure 4.20 F). The dark cells were identified as 
oligodendrocytes because they clearly wrapped axons (Figure 4.20 F), and possibly 
were attempting to remyelinate. Interestingly, we found that the number of 
mitochondria within axons was increased in the spinal cord of 28-week-old DKO mice 
(Figure 4.20 G). Consistently, in the crude myelin fraction, the mitochondrial proteins 
were increased in the DKO mice (Figure 4.20 H). In line with previous studies that 
demyelinated axons increase mitochondrial content to fulfil their energy demand 
(Andrews et al., 2006; Mahad et al., 2009). AMP-activated protein kinase (AMPK) is a 
cellular energy sensor (Hardie et al., 2012). Remarkably, the activated form of AMPK 
phosphorylated at Thr 172 was upregulated in the spinal cord of 13-week-old DKO 
mice and in the brain of 28-week-old DKO, while the total AMPK level was not altered 
(Figure 4.20 I). Hence, our results indicate that the loss of the m-AAA protease in 
oligodendrocytes causes progressive demyelination and influences profoundly energy 
homeostasis. 
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Figure 4.20 Progressive axonal demyelination and energy deficiency in DKO mice 
(A) Gallyas myelin staining of the forebrain and cerebellum sections from 28-week-old mice. n = 3 mice 
per genotype. (B) Representative semithin sections of the white matter of the lumbar spinal cord of 28-
week-old mice. Degenerating axons (arrow) and dark cells (asterisk) are prominent in DKO mice. Scale 
bar, 50 µm. (C, D) Quantification of dark cells (C) and myelinated axons (D) in the white matter of the 
spinal cord of 28-week-old mice. (E) G ratio of axons in the white matter of the lumbar spinal cord of 28-
week-old CTRL and DKO mice. n = 3 mice per group and in total 118 axons in the CTRL and 117 axons 
in the DKO were calculated. (F) Electron micrographs of the white matter of the lumbar spinal cord of 
CTRL and DKO at the indicated ages. Progressive myelin defects and secondary axonal degeneration 
(arrows) were evident in the spinal cord of DKO mice. Arrowheads indicate adaxonal detachment of 
myelin, while an arrow with two heads points to myelin folding. Several axons showed thin myelin 
layers, a feature of remyelination (empty stars). A dark remyelinating oligodendrocyte surrounding a 
swollen axon has membrane-like myelin debris is indicated with an asterisk. n = 3 mice per genotype 
were used in all experiments. Scale bar, 1 µm. (G) Quantification of the number of axonal mitochondria 
in the spinal cord of CTRL and DKO mice at 28 weeks of age (n = 3 mice per group; in total 404 axons in 
CTRL and 479 axons in the DKO were assessed). (H) Mitochondrial proteins were increased in the crude 
myelin fractions isolated from the brain CTRL and in DKO at 28 weeks of age were. (I) Western blots 
revealed phospho-AMPKα (Thr172) upregulation in the spinal cord and in the brain of DKO mice at 13 
weeks and 28 weeks of age, respectively.  
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We further addressed whether axonal demyelination is associated with 
neuroinflammation. In the DKO mice at 28 weeks of age, western blot analysis 
confirmed myelin protein MBP and CNP reduction, and astrocytes marker GFAP 
upregulation (Figure 4.21 A). At 10 weeks of age, DKO mice showed only mild 
demyelination in the spinal cord; however, the GFAP levels were increased in the brain 
and in the spinal cord (Figure 4.21 B). These results were further comfirmed by 
immunostaining of MBP and GFAP antibodies in the brain. Astrocytes were amplified 
in number and were intensively stained by the GFAP antibody in the corpus callosum of 
DKO mice at both 10 weeks and 28 weeks of age, whereas the staining of MBP was 
comparable at 10 weeks and reduced at 28 weeks of age (Figure 4.21 C). Notably, 
immunostaining with microglia marker IBA1 also revealed obvious microglial 
activation represented by morphological enlargement and quantitative increase in the 
DKO mice at 28 weeks of age (Figure 4.21 C). Taken together, these data suggest that 
inflammation is evoked in the DKO mice, and astrogliosis is an early event that 
precedes microgliosis and myelination defect. 
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Figure 4.21 Early neuroinflammation followed by axonal demyelination in the DKO mice. 
(A) Western blots showed a reduction of myelin proteins MBP and CNP in both brain and spinal cord of 
28-week DKO mice. The number of astrocytes stained by GFAP antibody was obviously increased in 
both tissues at this age. (B) At 10 weeks of age, while myelin proteins in the brain of DKO mice were not 
evidently reduced, the levels of GFAP already were upregulated suggesting that astrogliosis was an early 
event prior to overt demyelintion. In the spinal cord, the myelin proteins MBP and CNP were slightly 
decreased at 10 weeks of age. (C) Immunostaining of MBP, GFAP, and IBA1 in the corpus callosum 
(CC) of coronal brain sections of CTRL and DKO mice at the indicated ages. Demyelination in the DKO 
mice was associated with astrogliosis and microglial activation. n = 3 mice per group at each time point. 
Scale bar, 100 µm. 
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4.5.6 Rapid loss of targeted cells in the DKO mice 
The early-onset astrocytes activation followed by demyelination prompted us to 
investigate the fate of oligodendrocytes temporally in the central nervous system. Using 
the quadruple PLP1-CreERT/Afg3l2flox/flox/Afg3l1-/-/ROSA26+/SmY line, we observed 
rapid and progressive mt-YFP+ oligodendrocytes loss in the corpus callosum of DKO 
mice older than 6 weeks of age. Only a few mt-YFP+ oligodendrocytes existed at 28 
weeks of age (Figure 4.22 A-B). Cell loss was in line with what was previously 
observed in the skin and in the peripheral nerves. Moreover, the number of mature 
oligodendrocytes stained by APC was significantly declined in the brain and in the 
spinal cord of DKO mice at 10 weeks of age (Figure 4.22 C-E). Interestingly, APC+ 
oligodendrocytes were replenished at 28 weeks of age (Figure 4.22 A, C), indicating 
compensatory proliferation and differentiation of untargeted oligodendrocyte precursors. 
Indeed, APC+ cells appeared enlarged (Figure 4.23 A-B) and more intensively stained 
by Olig2 (Figure 4.23 A), a key transcription factor necessary for oligodendrocyte 
development and expressed at high levels in oligodendrocyte precursors and at low 
levels in mature oligodendrocytes (Kuhlmann et al., 2008; Mei et al., 2013). Despite 
this, when I quantified Olig2+ cells in the corpus callosum, I did not observe statistical 
difference between CTRL and DKO mice at 6 weeks, 10 weeks and 28 weeks of age 
(Figure 4.23 C-D). Together, these results illustrate that ablation of the m-AAA protease 
in oligodendrocytes in adult mice causes cell death within a few weeks followed by 
compensatory oligodendrocyte precursor replenishment. 
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Figure 4.22 Death of targeted oligodendrocytes and compensatory proliferation of untargeted 
oligodendrocytes in DKO mice 
(A) Immunofluorescence double staining of GFP and APC in coronal brain sections from mice at 
indicated ages. GFP staining allowed us to visualize targeted mt-YFP+ cells, and mature oligodendrocytes 
were labeled by APC in the corpus callosum. Nuclei were counterstained with DAPI. CC: corpus 
callosum. Arrowhead shows an enlarged APC+ mature oligodendrocyte without the mt-YFP signal. (B) 
Quantification of mt-YFP+ cells in the corpus callosum revealed rapid progressive loss of targeted 
oligodendrocytes in the DKO. (C) Quantification of APC+ cells in the corpus callosum. (D-E) 
Immunofluorescence staining of APC+ cells in the white matter (D) and in the grey matter (E) of the 
spinal cord of 10-week-old CTRL and DKO mice. (F) Quantification of APC+ cells in the grey matter of 
the spinal cord. For all experiments, n = 3 or 4 mice per group at each time point. 
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Figure 4.23 Oligodendrocyte regeneration in the brain of DKO mice. 
(A) Double immunofluorescence staining of APC and Olig2 in the corpus callosum of CTRL and DKO 
mice at 28 weeks of age. Enlarged APC+ oligodendrocytes were more intensively stained by Olig2 in the 
DKO mice, suggesting these oligodendrocytes were developing. Scale bar, 50 µm. (B) Quantification of 
the size of APC+ oligodendrocytes in the corpus callosum of CTRL and DKO mice at 28 weeks of age. n 
= 3 mice per group, and in total 244 oligodendrocytes in the CTRL and 205 oligodendrocytes in the DKO 
were measured. (C, D) Immunofluorescence staining and quantification of Olig2+ cells in the corpus 
callosum (CC) of CTRL and DKO mice at the indicated ages. n = 3 mice per genotype per age. 
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To explore the mechanism of oligodendrocytes death caused by the loss of the m-AAA 
protease, we firstly examined the morphology and functionality of the mitochondria. 
Interestingly, mitochondria appeared fragmented and swollen in DKO mice at 6 weeks 
of age, only 2 weeks after tamoxifen injection. At this age, mitochondria in targeted 
cells tended to be less intensively stained for COX1 in the DKO mice. Strikingly, at 8 
weeks of age, COX1 staining disappeared (Figure 4.24 A), revealing that deletion of m-
AAA protease causes loss of the COX1 subunit of the respiratory chain complex IV and 
a potential impairment of mitochondrial respiration. Furthermore, in situ TUNEL assay 
detected significantly more apoptotic cells in the corpus callosum of 7-week-old DKO 
mice (Figure 4.24 B, C). Consistently, ultrastructural study showed mitochondrial 
abnormalities, and apoptotic features, such as intact cell membrane and condensed 
nucleus, in the oligodendrocytes of DKO mice (Figure 4.24 D). It has been shown that 
cytochrome c release from the mitochondria may lead to apoptosis (Cai et al., 1998), 
hence, we performed cytochrome c immunostaining in the brain sections from 8-week-
old mice. Cytochrome c was localized into mitochondria in the WT mice; however, it 
was released from the swollen mitochondria in the DKO mice (Figure 4.24 E). In 
summary, deletion of the m-AAA protease in oligodendocytes impairs mitochondrial 
respiration, induces cytochrome c release and eventually causes apoptosis. 
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Figure 4.24 Loss of the m-AAA protease in oligodendrocytes causes mitochondrial dysfunction and 
triggers apoptotic death 
(A) Deconvoluted single-plane confocal images of double immunofluorescence staining of mt-YFP and 
COX1 in WT and DKO mice at the indicated age. mt-YFP+ mitochondria in DKO lost COX1 staining. n 
= 3 mice per group per time point. Scale bar, 1 µm. (B) Representative images of TUNEL assay in the 
corpus callosum of mice at 7 weeks of age. n = 4 mice per group. Scale bar, 10 µm. (C) Quantification of 
TUNEL+ cells in the corpus callosum. Data are plotted as individual values from each mouse with mean ± 
S.E.M. (D) Ultrastructural analysis showed apoptotic oligodendrocytes in the corpus callosum of DKO 
mice at 8 weeks of age. n = 3 mice per group. Scale bar, 1 µm. (E) Deconvoluted single-plane confocal 
images of double immunofluorescence staining of GFP and cytochrome c in WT and DKO mice at 8 
weeks of age. n = 3 mice per group. Scale bar, 1 µm. 
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5.1 Mitochondrial morphology alteration upon loss of the m-AAA 
protease 
Aberrant mitochondrial dynamics has been implicated in the pathogenesis of 
neurodegenerative diseases (Cho et al., 2010; Knott et al., 2008; Lu, 2009), such as 
Charcot-Marie-Tooth disease type 2A (Kijima et al., 2005; Zuchner et al., 2004) and 
autosomal dominant optic atrophy (Alexander et al., 2000), caused by mutations of 
mitochondrial fusion gene Mfn2 and Opa1 respectively. Little is known about the cell-
autonomous role of mitochondrial dynamics in neurodegeneration. In this study, I have 
shown that deletion of mitochondrial protease AFG3L2 in both forebrain neurons and 
myelinating glial cells cause similar mitochondrial fragmentation and enlargement; 
however, the fate of these cells is distinct. Early neuronal death and normal 
oligodendrocyte survival highlight that neurons are preferentially susceptible to 
mitochondrial fission/fusion imbalance. This is reasonable as neurons are highly 
polarized cells with the axonal extension up to one meter in humans (Williamson et al., 
1996), they are particularly vulnerable to mitochondrial morphological disturbance, 
which influences the activity of respiratory complexes, Ca2+ buffering and quality 
control maintenance (Burte et al., 2015; Chan, 2006; Chen and Chan, 2009; Cho et al., 
2010; Itoh et al., 2013).  
On the other hand, the significance of mitochondrial dynamics in glial cells has not been 
extensively investigated yet. Depletion of COX10 or Tfam in Schwann cells causes 
mitochondrial enlargement (Funfschilling et al., 2012; Viader et al., 2011); however, 
mitochondrial fusion and fission in these mouse models have been not explored in detail, 
presumably due to lack of any dramatic difference. In comparison with neurons, a 
specific feature of glial cells is the capability of glycolysis (Kasischke et al., 2004; 
Pellerin and Magistretti, 1994; Vega et al., 2003). Whether the effects of mitochondrial 
dynamics abnormalities in glycolytic cells are attenuated remains presently not well 
understood. In this study, disturbed mitochondrial morphology in Afg3l2-deficient 
myelinating cells and long-term survival of these cells, support the idea that glial cells 
could be more tolerant to mitochondrial dynamics abnormalities. Moreover, 
mitochondrial fragmentation per se may serve as a cellular stress response and facilitate 
cellular adaption dependent on the metabolic profile of the cell. Consistently, 
mitochondrial fission is utilized by brown adipocytes to increase energy expenditure by 
shifting nutrient oxidation towards thermogenesis (Wikstrom et al., 2014).  
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We have found that mitochondrial fusion protein OPA1 is cleaved and fission protein 
DRP1 and active form of DRP1 at phosphorylation site Ser616 are decreased in the 
brain of Afg3l2 full-body knockout mice. AFG3L2 deficiency triggers stress-induced 
OMA1 peptidase activation (Ehses et al., 2009), and OMA1 mediates the degradation of 
OPA1 long isoforms into short isoforms (Baker et al., 2014; Ehses et al., 2009). 
Furthermore, short isoforms of OPA1 promote mitochondrial fission and inhibit fusion, 
resulting in mitochondrial fragmentation (Anand et al., 2014). Normally, enhanced 
mitochondria fission should recruit more active DRP1 to mitochondria (Ingerman et al., 
2005; Legesse-Miller et al., 2003); however, we unexpectedly observed reduced levels 
of total DRP1, active phospho-DRP1 S616 and DRP1 in mitochondrial fraction. 
Interestingly, DRP1 is the only fusion/fission protein that shows an alteration or a 
reduction in SCA28 patient lymphoblasts (Mancini et al., 2013). Thus, we open the 
question whether decreased recruitment of DRP1 to mitochondria might be a 
compensatory mechanism to balance excessive fission.  
Postnatal deletion of Afg3l2 in forebrain-neurons and myelinating cells circumvents the 
potential impacts on embryonic development; nevertheless, similar mitochondrial 
morphological alteration still occurs, which highlights the essential role of AFG3L2 to 
maintain proper mitochondrial morphology and function in neuronal tissues. AFG3L2 
plays pleiotropic roles in mitochondria, including processing of respiratory chain 
subunits and mitochondrial ribosomal protein MRPL32 in mitochondria (Bonn et al., 
2011; Hornig-Do et al., 2012; Leonhard et al., 1996; Nolden et al., 2005) and 
mitochondrial Ca2+ buffering (Maltecca et al., 2015; Maltecca et al., 2012). Is there a 
primary cause to induce mitochondrial fragmentation and enlargement in the absence of 
AFG3L2 protease? Based on the published studies, this question might be difficult to 
address currently, however, some hints can be obtained. Considering lack of significant 
OPA1 processing in the brain of Surf1 KO, Sco2 KO/KI and Nduf4 KO mice (this 
study), which clearly show respiratory complex deficiency (Ingraham et al., 2009; 
Viscomi et al., 2011; Yang et al., 2010), it is unlikely that purely affecting 
mitochondrial respiration to a certain extent triggers extensive mitochondrial fusion and 
fission disturbance in vivo. Since mitochondrial fission is also regulated by 
mitochondrial membrane potential, ROS levels and calcium homeostasis (Baker et al., 
2014; Jeyaraju et al., 2009), these aspects should be taken into account for the 
mitochondrial fragmentation resulting from AG3L2 loss. Further studies to uncouple 
  98 
the role of AFG3L2 are required to understand the primary cause of mitochondrial 
fragmentation in cells lacking AFG3L2.   
Additionally, mitochondrial fragmentation is regarded as a prerequisite for autophagy or 
mitophagy to eliminate damaged mitochondria or mitochondrial proteins (Narendra et 
al., 2008; Twig et al., 2008; Youle and van der Bliek, 2012). Whether autophagy or 
mitophagy is enhanced in the Afg3l2-deficient cells remains not well known. 
Remarkably, deficiency of AFG3L2 not only causes mitochondrial fragmentation, but 
also mitochondrial enlargement. Speculatively, these gigantic mitochondria would be 
difficult to be removed by autophagy. Regarding the phenotype of mitochondrial 
enlargement, it is noteworthy to mention that the non-specific mitochondrial 
permeability transition pore (MPTP) opening enables free passage of molecules up to 
about 1.5 kDa into the mitochondria leading to matrix swelling, under pathological 
condition of mitochondrial calcium overload (Bernardi, 2013; Halestrap, 2009). 
Investigating calcium influx and determinating which component of the MPTP is 
affected will allow us to know the mechanism of mitochondrial enlargement alteration 
upon loss of AFG3L2. 
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5.2 Tau hyperphosphorylation evoked by AFG3L2 deficiency in 
neurons 
Tau is a microtubule-associated phosphoprotein abundantly expressed in neurons, 
which stabilizes axonal microtubules (Breuzard et al., 2013; Butner and Kirschner, 1991; 
Cleveland et al., 1977; Drubin et al., 1986; Shin et al., 1991; Stoothoff and Johnson, 
2005). In AD, many kinases have been shown to increase their activity and trigger tau 
hyperphosphorylation (Martin et al., 2013b). Hyperphosphorylated tau detaches from 
microtubules, aggregates into paired helical filaments and results in microtubule 
breakdown, intracellular transport defect and ‘dying-back’ of axons (Mandelkow and 
Mandelkow, 1998). Remarkably, in our two Afg3l2 mouse models, constitutive full-
body knockout and conditional forebrain neuron-specific knockout, tau is 
hyperphosphorylated in the brain of both models.  
During development, tau is phosphorylated to match the period of active neurite 
outgrowth (Yu et al., 2009), Since Afg3l2 full-body knockout mice generally die before 
at P16 (Maltecca et al., 2008) when the kinases are still active (Yu et al., 2009), it could 
be difficult to detect the kinases up-regulation at this stage. Not surprisingly, none of the 
kinases we assessed was hyperactivated neither in the total brain lysates nor 
mitochondrial fraction. In the absence of AFG3L2, mitochondrial respiration is 
defective (Almajan et al., 2012; Maltecca et al., 2008) because of mitochondrial protein 
synthesis impairment (Almajan et al., 2012). Inefficient mitochondrial respiration 
further leads to decreased ATP synthesis rate (Maltecca et al., 2008) and ultimately 
cAMP elevation; besides, it may also result in raised ROS production. For instance, 
Afg3l2 haploinsufficiency mouse model shows increased ROS level at one year old 
(Maltecca et al., 2009). Consequence of the secondary effects of cAMP and ROS 
enhancement in the Afg3l2 full-body knockout mice might be difficult to detect because 
of the early death. In contrast, in the adult model, Afg3l2 is deleted postnatally, giving 
us relatively sufficient time for the analysis. Consequently, we found cAMP-dependent 
PKA and oxidative stress-induced ERK1/2 kinases activation in AFG3L2NKO mice 
(Kondadi et al., 2014). Notably, tau hyperphosphorylated sites including T181, S199, 
S202, T205 and S396 in AFG3L2-deficient mouse models have been found in 
Alzheimer's disease patients shown to be phosphorylated by PKA and ERK1/2 (Martin 
et al., 2013b). On the other hand, tau phosphorylation is also regulated by phosphatase 
activity (Braithwaite et al., 2012; Martin et al., 2013a). Downregulation of phosphatases, 
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such as protein phosphatase 2A, has been implicated in the pathogenesis of AD. 
Therefore, the phosphatases activity could be a direction to understand tau pathogenesis 
of neurodegenerative diseases associated with AFG3L2 deficiency.  
No evident hyperphosphorylated tau levels in the brain of mitochondrial respiratory 
chain complex-deficient Surf1 KO, Sco2 KO/KI and Ndufs4 KO mice, reveals a 
particular link of the m-AAA protease and tau phosphorylation. Interestingly, PHB1/2, 
form ring-shaped scaffolds in the inner mitochondrial membrane that regulate the 
turnover of membrane proteins by the m-AAA protease (Merkwirth and Langer, 2009; 
Steglich et al., 1999), ablation of which in forebrain neurons with the same CaMKIIα-
Cre line also leads to tau hyperphosphorylation (Merkwirth et al., 2012). Thus, our data 
provide genetic evidence for a casual relationship of the m-AAA protease and tauopathy. 
Interestingly, tau reduction produces beneficial effects on mitochondrial transport in a 
mouse model of Alzheimer's disease (Vossel et al., 2010). Likewise, downregulation of 
tau partially rescued mitochondrial anterograde transport defect in Afg3l2 knockdown 
primary neurons (Kondadi et al., 2014). Additionally, in these neurons, antioxidants, 
such as N-acetyl-cysteine and vitamin E, restored the mitochondrial transport 
impairment, further implying the role of ROS in the causative signaling pathway 
(Kondadi et al., 2014).  
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5.3 Physiological role of AFG3L1 in the mouse 
In humans, AFG3L1 is pseudogene, and is transcribed into four mRNA isoforms that 
are not translated (Kremmidiotis et al., 2001). AFG3L1, which shares highly sequence 
identity (68.5%) with its homolog AFG3L2, is expressed in mouse in tissue-specific 
manner (Koppen et al., 2007; Sacco et al., 2010). However, no mouse model of Afg3l1 
has been published yet. Here we generated a full-body knockout mouse model of Afg3l1 
and have shown that loss of Afg3l1 can be tolerated in mouse. In contrast to severe 
developmental defects of Afg3l2 null mice, Afg3l1 full-body knockout mice have 
normal growth curve and display no obvious sign of neurodegeneration at least till one 
year of age. Our study and others have shown that AFG3L1 is not highly expressed in 
the brain (Koppen et al., 2007; Sacco et al., 2010), suggesting that the complexes of 
mitochondrial m-AAA protease, formed by AFG3L2 and paraplegin, are sufficient for 
mitochondrial dynamics and cell survival.  
Surprisingly, despite high expression levels of AFG3L1 and AFG3L2, in the liver of 
Afg3l1 full-body knockout (this study) or Afg3l2 null mice (Ehses et al., 2009), no 
abnormal OPA1 cleavage was observed, indirectly suggesting normal mitochondrial 
dynamics. Consistently, the morphology of mitochondria in the liver in Afg3l2 null mice 
was comparable to the wildtype mice (Maltecca et al., 2008). How liver mitochondria 
cope with the loss of the m-AAA protease is a very interesting question, which has to be 
addressed. Further investigations are required to understand whether the function of the 
m-AAA protease correlates with the features of mitochondria among different tissues. 
Despite the fact that AFG3L1 may compensate the loss of AFG3L2 or paraplegin, most 
published m-AAA protease mouse studies till now have neglected the existence of 
AFG3L1 in the mouse models (Almajan et al., 2012; Ferreirinha et al., 2004; Kondadi 
et al., 2014; Maltecca et al., 2008; Maltecca et al., 2015; Maltecca et al., 2009). 
Therefore, the availability of Afg3l1 full-body knockout mouse model will allow future 
studies to better model the human diseases associated with the m-AAA protease 
mutations. 
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5.4 AFG3L2 is required for oligodendrocyte maturation but is 
dispensable for the survival of adult oligodendrocytes 
Previous in vitro studies have shown that mitochondria are required for oligodendrocyte 
differentiation and myelin production, and whether mitochondrial dysfunction causes 
glial cell demise is not clear (Schoenfeld et al., 2010; Ziabreva et al., 2010). In the 
absence of AFG3L2, the viability of oligodendrocytes is not affected; instead, their 
maturation is impaired as shown by the significant reduction of mt-YFP+ cells not 
localized with mature oligodendrocytes marked by APC antibody. This would make a 
significant consequence if Afg3l2 were depleted during early postnatal or developmental 
stage when mature oligodendrocytes are required during the peak of myelin formation. 
Given the fact that PLP1-CreERT transgenic line targets not only myelinating cells but 
also astrocytes and neurons during development (Guo et al., 2009; Michalski et al., 
2011), it is difficult to explore the role of AFG3L2 or m-AAA protease in the process of 
myelin formation using this promoter. Although AFG3L1 and paraplegin are expressed 
at low levels in oligodendrocytes, presumably the amount of m-AAA protease 
composed of AFG3L1 and paraplegin in these cells is sufficient for mitochondrial 
quality control maintenance and cell survival for relatively long time. However, 
ultimately myelinating cells lacking AFG3L2 become sick and cannot support long-
term axonal integrity and proper myelin maintenance. Probably this is one explanation 
for axonal degeneration and dysmyelination in the 90-week-old mice. 
How to explain the long-term survival of myelinating cells in the absence of AFG3L2? 
In vivo studies conducted by other groups have proposed that oligodendrocytes and 
Schwann cells utilize glycolysis to survive when mitochondrial respiration is impaired 
(Funfschilling et al., 2012; Viader et al., 2011). This hypothesis might be applied to our 
mouse model, in which low amount of the m-AAA protease composed by AFG3L1 and 
paraplegin maintains mitochondrial quality control, and adapted metabolism supports 
cell survival and axonal integrity.  
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5.5 Lack of the m-AAA protease causes death of myelinating cells 
In this study, we generated and characterized a mouse model that lacks the whole m-
AAA protease complexes for the first time. Interestingly, despite that the loss of 
AFG3L2 does not affect the viability of oligodendrocytes, deletion of entire m-AAA 
protease causes rapid cell death and results in progressive motor deficit and hair greying 
of the mutant mice.  
5.5.1 Oligodendrocyte death and axonal demyelination in the central nervous 
system 
In the literature, common approaches to ablate oligodendrocytes in the mouse used 
either diphtheria toxin (DTX)-diphtheria toxin receptor (DTR) system or genetically 
activation of diphtheria toxin fragment A (DTA) expression in oligodendrocytes (Ghosh 
et al., 2011; Gritsch et al., 2014; Locatelli et al., 2012; Oluich et al., 2012; Traka et al., 
2010; Traka et al., 2016). Here, we induced oligodendrocytes death by mitochondrial m-
AAA protease deletion. To my knowledge, only two mouse studies carrying deletion of 
mitochondrial genes in myelinating cells have been reported so far (Funfschilling et al., 
2012; Viader et al., 2011). Coincidentally, in both studies, Schwann cells or 
oligodendrocytes survive well in the absence of mitochondrial transcriptional factor 
Tfam or respiratory complex IV assembly factor Cox10, as these cells have the 
capability of glycolysis (Funfschilling et al., 2012; Viader et al., 2011). Thus, 
independent from oxidative capacity, an anti-cell death function of the m-AAA protease 
is highlighted. Another evidence to support the idea that the functions of m-AAA 
protease are beyond just having an impact on mitochondrial respiration is that deleting 
postnatally Afg3l2 in forebrain neurons using CaMKIIα-Cre line causes massive 
neuronal loss at 2 months of age (Kondadi et al., 2014), which is much earlier than at 4 
to 5 months of deleting OXPHOS genes Tfam or Cox10 using the same CaMKIIα 
promoter and Cre recombinase strategy (Diaz et al., 2012; Fukui et al., 2007; Sorensen 
et al., 2001).  
Our work demonstrates that deletion of whole m-AAA protease in oligodendrocytes 
leads to apoptosis. Consistently, apoptotic pathway activation is revealed in the SCA28 
patients by genome-wide expression profiling (Mancini et al., 2013). Moreover, the 
mitochondrial i-AAA protease YME1L deficiency in human embryonic kidney 293 
cells or in Drosophila leads to impaired apoptotic resistance (Qi et al., 2016; Stiburek et 
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al., 2012). However, increase necrotic cell death is revealed in the YME1L knockout 
cardiomyocytes (Wai et al., 2015). Notably, our data demonstrate that the death of 
myelinating cells is independent of mitochondrial dynamics, and presumably also is not 
caused by respiration deficiency. However, based on our experiments, we cannot 
exclude that there are other concomitant cell death pathways upon loss of m-AAA 
protease. Further studies are required to explore unknown substrates or interactors of m-
AAA protease, which might directly or indirectly play a role in apoptosis or other cell 
death pathways.  
Since one of the significant functions of oligodendrocytes is to produce myelin (Bradl 
and Lassmann, 2010), ablation of oligodendrocytes in adult circumvents gene deletion 
during the period of myelin formation and more possible affects myelin maintenance. 
Indeed, oligodendrocytes death is followed by progressive axonal demyelination and 
degeneration. In line with our observation, demyelination occurs as early as several 
weeks after oligodendrocyte ablation (Locatelli et al., 2012; Pohl et al., 2011; Traka et 
al., 2016). Interestingly, prior to the overt demyelination, I have shown that astrogliosis 
is an early event accompanied by oligodendrocytes demise, and is followed by 
microglial activation. The roles of astrogliosis and microgliosis in demyelinating 
diseases are controversial, both protective and destructive effects are being discussed 
(Aguzzi et al., 2013; Williams et al., 2007). However, in recent studies, astrocytes and 
microglia are suggested to exert beneficial roles (Kocur et al., 2015; Lampron et al., 
2015; Masuch et al., 2015; Nikolakopoulou et al., 2013; Skripuletz et al., 2013). For 
instance, astrocytes secrete chemokine to recruit microglia to remove myelin debris, 
which facilitates oligodendrocytes regeneration during remyelination (Skripuletz et al., 
2013). Although the consequence of astrocyte and microglia activation in our double 
mutants needs deep investigation, complete replenishment of oligodendrocytes in these 
mice indicates that oligodendrocyte regeneration is not impaired. Thus, beneficial 
effects of astrogliosis and microgliosis in this context are favored.  
Oligodendrocyte regeneration, in other words, oligodendrocyte precursor cells (OPC) 
proliferation, is considered as a prerequisite for myelin repair in demyelinating 
disorders, such as multiple sclerosis (MS) (Franklin and Ffrench-Constant, 2008). As 
expected, oligodendrocyte regeneration results in remyelination to a certain extent, but 
our mice still show axonal demyelination and degeneration. One explanation is that 
regenerated oligodendrocytes have inadequate myelination capability. Secondly, axonal 
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damage or loss may occur during the gap of oligodendrocyte death and regeneration. 
Due to lack of more time-course analyses, I could not catch the time point when the 
OPC generation takes place. Additionally, it has been shown that genetic 
oligodendrocyte ablation triggers sufficiently adaptive autoimmune response against 
myelin (Traka et al., 2016). Whether oligodendrocyte death in our double mutant mice 
is associated with T- and B-cell infiltration in the CNS is still an open question.  
Mitochondrial accumulation in the axons of DKO mice is of particular interest because 
increased mitochondrial content has been implicated within demyelinated axons in 
chronic myelin-deficient Shiverer mouse or in MS patients (Andrews et al., 2006; 
Mahad et al., 2009; Zambonin et al., 2011). Syntaphilin (SNPH), which controls axonal 
mitochondria docking through the interaction with microtubules (Kang et al., 2008), is 
upregulated in Shiverer mouse or in MS patients (Joshi et al., 2015; Mahad et al., 2009). 
Further studies demonstrate that mitochondrial mobilization by deletion of SNPH, 
deteriorates the survival of demyelinated axons in acute demyelination (Ohno et al., 
2014), but produces benefits in the chronic demyelinating Shiverer mouse (Joshi et al., 
2015). Thus, a biphasic model is proposed for the role of SNPH during MS: 
mitochondrial anchoring by SNPH is adaptive in the early phase and maladaptive in the 
late phase (Joshi et al., 2015). The expression level of SNPH in the absence of m-AAA 
protease remains undetermined. Considering the progressive process of demyelination 
and AMPK activation in our DKO mice, it is conceivable that stationary mitochondrial 
congestion is compensatory to fit the energy-demand in the demyelinated axons; 
however, exhausted mitochondria might get stuck in the axons and ultimately generate 
substantial molecules such as ROS to fuel a vicious cycle (Joshi et al., 2015).  
5.5.2 Peripheral neuropathy 
In contrast to extensive axonal demyelination in the CNS of the DKO mice, moderate 
phenotype was observed in the PNS. This is possibly because the efficiency of Cre-
mediated recombination under PLP1 promoter in the PNS is much less than in the CNS 
(Doerflinger et al., 2003). Although PLP1 only constitutes 0.15% of total myelin 
proteins in the murine sciatic nerve (Patzig et al., 2011), it is expressed in both 
myelinating and nonmyelinating Schwann cells in adult mouse (Jiang et al., 2000). Here 
we induced the Cre recombinase activation using PLP1-CreERT line at 4 weeks, a time 
point when it is still enigmatic which cell populations in the PNS expressed PLP1. 
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Targeted Schwann cells are significantly diminished in the DKO mice, and our results 
highlight that the loss of m-AAA protease preferentially affects nonmyelinating 
Schwann cells and small C-fibers. This is in line with previous findings that these cells 
are more susceptible to mitochondrial dysfunction in a mouse model of Tfam deletion in 
Schwann cells (Viader et al., 2011). The susceptibility of unmyelinating small-caliber 
axons is also shown in the diabetic peripheral neuropathies (Kennedy et al., 1996; 
Polydefkis et al., 2004) and small-fiber sensory neuropathies (Lacomis, 2002; Sommer 
and Lauria, 2007). However, since small fibers are sensory nerves, their sensory 
phenotype of our DKO needs to be further explored. Mild demyelination and adaxonal 
myelin detachment of large-caliber axons in the 28-week DKO mice indicate that motor 
nerve fibers are eventually damaged, which may contribute to the motor deficit in the 
beam-walking test of these mice.  
After nerve injury, Schwann cells digest myelin by selective autophagy-myelinophagy 
for regeneration (Gomez-Sanchez et al., 2015). This is a particular feature of Schwann 
cells in comparison with oligodendrocytes (Brosius Lutz and Barres, 2014), therefore, it 
is not surprising that we could observe few myelin debris in the PNS but numerous 
myelin debris accumulation in the CNS of the DKO mice. Failure to detect 
myelinophagy in the Schwann cells lacking the m-AAA protease is probably owing to 
very low targeting efficiency in the PNS therefore limited number of autophagosomes.  
5.5.3 Melanocytes reduction and hair greying in the skin 
A remarkable phenotype of our DKO mice is age-related premature hair greying. We 
have shown that loss of melanocytes is the cause of hair greying. Skin melanocytes 
originate from two sources: one is directly from neural crest cells with dorsal migration 
(Rawles, 1947), the other is indirectly from neural crest-derived Schwann cell 
precursors with ventral migration (Adameyko et al., 2009; Nitzan et al., 2013). 
Transcription factor FoxD3 regulates the balance between these two populations of 
melanocytes (Nitzan et al., 2013). Additionally, transcriptomic analysis of embryo skin 
reveals that PLP1 gene is expressed in melanoblasts (Colombo et al., 2012). Moreover, 
it has been shown that melanocytes are targeted by PLP1-promoter driven Cre 
expression during embryogenesis (Leone et al., 2003). PLP1-Cre is active in Schwann 
cell precursors-bipotential progenitors of Schwann cells and melanocytes, rather than in 
melanocytes (Adameyko et al., 2009). However, all these studies are conducted during 
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embryonic development. Is PLP1 expressed in melanoblasts/melanocytes in adult? 
What are the cellular sources for melanoblasts/melanocyte stem cells in adult? Are 
Schwann cells /Schwann cell precursors contributing to them in adult? All these 
questions are not clear.  
Our preliminary data unveil that the reporter mitochondrial YFP signal was localized to 
mature melanocytes and melanoblasts after activating Cre recombinase, and c-KIT+ 
melanocytes were diminished in the skin of the DKO mice. To my knowledge, these are 
the first findings suggesting that melanocytes/melanoblasts could be eventually targeted 
by inducible PLP1-CreERT line in adult mouse, and the mitochondrial m-AAA protease 
is essential for Schwann cell/melanocyte lineage survival. Based on our preliminary 
results, there are three hypotheses to explain the hair greying phenotype. First of all, at 4 
weeks of age, PLP1 promoter is expressed not only in myelinating cell lineage but also 
in melanocyte lineage; in other words, melanocytes are directly targeted by PLP1-
promoter driven Cre recombinase in adult. Although this is not in agreement with the 
observation that PLP1-Cre is not active in melanocytes at embryonic stages (Adameyko 
et al., 2009), our ‘direct’ evidence to support this hypothesis is that minor mitochondrial 
YFP signal was found in hair follicles in the skin as early as one day after tamoxifen 
induction (Julie Jacquemyn’s data not shown). However, if this were true for the DKO 
mice, I would expect to see an early dorsal hair greying phenotype since neural crest 
cells-derived melanocytes migrate dorsally. Instead, we saw a progressive forelimbs-
hindlimbs-ventral to lateral body wall-dorsal-head hair greying pattern. This is 
reminiscent of a previous study demonstrating that Schwann cell precursors give rise to 
a large number of melanocytes in the limbs, lateral and dorsal skin during the 
embryonic development (Adameyko et al., 2009). Furthermore, deletion of the m-AAA 
protease leads to dramatic Schwann cell death in the peripheral nerves and 
preferentially has early affects on nonmyelinating Schwann cells. Whether Schwann 
cell precursors exist in adulthood is still an open question. Interestingly, in bone marrow, 
adult nonmyelinating Schwann cells contact with hematopoietic stem cells (HSC) and 
express HSC factor TGF-β to regulate HSC hibernation (Yamazaki et al., 2011). Thus, 
nonmyelinating Schwann cells in the adult may express factors for melanocyte stem 
cells maintenance, or act as precursors instead of embryonic Schwann cell precursors. 
This brings me to the second hypothesis: the absence of the m-AAA protease causes 
nonmyelinating Schwann cells death, thereby leading to lack of Schwann cell-derived 
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melanocytes replenishment and ultimately resulting in hair greying. The third is 
accepting the former two hypotheses: the hair greying is caused partially by direct 
targeting melanocyte death and largely by loss of Schwann cell-originated melanocytes. 
This hypothesis is more preferable in the scenario of hair greying pattern, but does not 
exclude the possibility of directly targeting a small population of melanocytes.  
Skin biopsy has been widely used to investigate peripheral neuropathies (Sommer and 
Lauria, 2007), and skin denervation is one of the initial signs of pathology and 
correlates with disease progression (Ebenezer et al., 2007). Considering the phenotypes 
of peripheral neuropathies in the DKO mice, I would expect to see denervation in the 
skin of the aged mice, and this could potentially account for the hair greying because 
the source of melanocytes from Schwann cells-associated peripheral nerve is cut out.  
However, because of incompatibility of antibody applications or lack of optimization, I 
could not address this point yet. 
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5.6 Conclusions 
In summary, using various genetic mouse models, we have shown:  
1. Postnatal Lack of AFG3L2 in neurons triggers tau hyperphosphorylation, which 
provides new insights to the pathogenesis of neurodegenerative diseases associated 
with AFG3L2 mutations. 
2. AFG3L2 is highly expressed in oligodendrocytes, and AFG3L2 deficiency is 
sufficient to cause mitochondrial fragmentation in myelinating glial cells. 
3. Loss of AFG3L2 in neurons and myelinating glial cells shows similar mitochondrial 
morphological alterations, but the outcomes are distinct. Whereas neurons die rapidly, 
the survival of oligodendrocytes is not affected but their maturation is delayed. 
4. Afg3l1 full-body knockout mice display no neurological phenotype till one year old 
of age. AFG3L1 is dispensable for mitochondrial quality control when AFG3L2 is 
present. 
5. Despite the capacity of glycolysis in myelinating glial cells, these cells die in the 
absence of the m-AAA protease, indicating a novel role of the m-AAA protease to 
prevent cell death. 
6. Oligodendrocyte death caused by the m-AAA protease ablation results in progressive 
axonal demyelination and profound energy deficiency.  
7. In adulthood, deletion of the m-AAA protease using the PLP1-CreERT line leads to 
premature hair greying. 
Therefore, we have expanded the basic understanding of the m-AAA protease functions 
in neurons and myelinating cells. We also provide a valuable mitochondria-based 
animal model to study chronic demyelinating diseases. Further investigation to unravel 
cell death mechanism in the absence of m-AAA protease may suggest novel therapeutic 
target for human neurodegenerative diseases such as SCA28 and hair greying.
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Zusammenfassung 
Die m-AAA Protease ist ein hexamerischer Proteinkomplex, welcher sich in der inneren 
Membran des Mitochondriums befindet. Zum einen spielt die m-AAA Protease eine 
Rolle in der Weiterverarbeitung von speziellen Substraten, zum anderen ist sie wichtig 
für den Abbau fehlgefalteter Polypeptide. Im Menschen besteht die m-AAA Protease 
aus AFG3L2 und paraplegin. Mutationen in dem AFG3L2 Gen sind verbunden mit den 
Krankheiten dominante Spinozerebelläre Ataxia 28 und dem rezessiven spastic ataxia-
neuropathy syndrome 5 (SPAX5). Weiterhin wurde gezeigt, dass Mutationen in dem 
SPG7 Gen, welches für paraplegin codiert, zur Hereditären Spastischen Paraplegie 
führen kann. In der Maus gibt es neben AFG3L2 und paraplegin eine dritte m-AAA 
Untereinheit, genannt AFG3L1. Obwohl verschiedene Maus Krankheitsmodelle den 
neurodegenerativen Phenotypen der oben gennanten Krankheiten rekapitulieren 
konnnten, ist der molekulare Mechanismus der dem zu Grunde liegt noch nicht 
verstanden.  
In dieser Arbeit wurde mit Hilfe verschiedener Mausmodelle die zellautonome Funktion 
der m-AAA Protease in Neuronen und in Myelin produzierenden Zellen erforscht. Wir 
konnten zeigen, dass in Knock-Out-Mäusen, in denen AFG3L2 entweder im ganzen 
Körper oder spezifisch im Vorderhirn fehlt, Mitochondrien fragmentieren und 
anschwellen und dass das Protein tau hyperphosphoryliert wird. Weiterhin führt das 
Fehlen von AFG3L2 in ausgewachsenen Myelin produzierenden Zellen zu früh 
auftretenden mitochondrialen Abnormalitäten wie auch vorher in Neuronen beobachtet 
werden konnte. Im Gegensatz zu der Beobachtung in Neuronen, konnten wir keine 
reduzierte Lebensdauer der Myelin produzierenden Zellen feststellen. Desweiteren ist 
bekannt, dass Myelin produzierende Zellen Probleme in der Atmungskette durch 
Glykolyse kompensieren können. Interessanterweise konnten wir jedoch zeigen, dass 
der komplette Verlust der m-AAA Protease durch den Knock-out (KO) von Afg3l2 in 
einem Afg3l1 KO Hintergrund (Doppelter Knock-out (DKO)), zum absterben von 
Myelin produzieren Zellen führt, was letztendlich zum fortschreitenden Verlust des 
Myelins um das neuronale Axons führt. Ausserdem haben wir ein frühzeitiges Ergrauen 
der Haare in DKO Mäusen festgestellt, was auf den Verlust von Melanozyten 
zurückzuführen ist. 
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Zusammenfassend konnten wir zeigen, dass es einen zellautonomen Grenzwert für die 
m-AAA Protease gibt, welcher nicht unterschritten werden darf, da sonst das Überleben 
der Zelle in Gefahr ist. Die essentielle Rolle von AFG3L2 in der Vorbeugung gegen den 
Zelltod ist unabhänging von der Teilung und Fusionierung von Mitochondrien und der 
Fähigkeit der Zelle Oxidative Phosphorylierung zu bertreiben. Unsere Ergebnisse 
bringen neue Erkenntnisse über Krankheiten die mit dem Verlust der m-AAA Protease 
verbunden sind. Weiterhin können die von uns etablierten Mausmodelle wertvolle 
Werkzeuge in der Forschung über andere Krankheiten sein, die der Mitochondrialen 
Dysfunktion zu Grunde liegen. Dies könnte helfen andere neurodegenerative 
Krankheiten, wie Tauopahtien und Krankheiten, in denen eine Myelin Defizit vorliegt, 
besser zu erforschen. 
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